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Flavouring Group Evaluation 51, Revision 2 
(FGE.51Rev2): Consideration of alicyclic ketones and 
secondary alcohols and related esters evaluated by 
JECFA (59th meeting) structurally related to alicyclic 
ketones secondary alcohols and related esters in 
FGE.09Rev6 (2015) 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings 
and Processing Aids (CEF) 
Abstract 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) of the 
European Food Safety Authority was requested to consider evaluations of flavouring substances 
assessed since 2000 by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), and to 
decide whether further evaluation is necessary, as laid down in Commission Regulation (EC) No 
1565/2000. The substances were evaluated through a stepwise approach that integrates information 
on structure-activity relationships, intake from current uses, toxicological threshold of concern, and 
available data on metabolism and toxicity. The present consideration concerns a group of 24 alicyclic 
ketones and secondary alcohols and related esters evaluated by JECFA (59th meeting in 2002 and 
63rd meeting in 2004). This revision is made due to inclusion of four additional substances cleared for 
genotoxicity concern compared to the previous version [FL-no: 07.033, 07.094, 07.112 and 07.140]. 
The Panel concluded for 23 substances that these do not give rise to safety concerns at the levels of 
dietary intake, estimated on the basis of the MSDI approach [FL-no: 02.209, 07.034, 07.035, 07.045, 
07.094, 07.095, 07.098, 07.112, 07.126, 07.129, 07.140, 07.148, 07.149, 07.172, 07.179, 07.180, 
07.257, 09.027, 09.140, 09.160, 09.230, 09.464 and 09.930]. However, for all substances use levels 
are needed to calculate the mTAMDIs in order to identify those flavouring substances that need more 
refined exposure assessment and to finalise the evaluation. Besides the safety assessment of these 
flavouring substances, the specifications for the materials of commerce have been considered and are 
adequate for 21 substances. For [FL-no: 07.094 and 07.112], information on the solubility in water 
and ethanol is missing. The chemical identity could not be unambiguously confirmed for substance 
[FL-no: 07.033]. Therefore the Panel could not consider the JECFA evaluation of this substance and 
information as to its chemical identity should be submitted. 
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Summary 
Following a request from the European commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) evaluations of flavouring substances assessed since 2000, and 
to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) No 
1565/2000. These flavouring substances are listed in the Register, which was adopted by Commission 
Decision 1999/217/EC and its consecutive amendments. 
The present revision of FGE.51, FGE.51Rev2, is due to new genotoxicity data evaluated in 
FGE.212Rev3 (EFSA CEF Panel, 2015a), which deals only with the genotoxic potential of 
α, β-unsaturated flavouring substances. Based on these data, the Panel concluded that the data 
available could rule out the concern for genotoxicity for [FL-no: 07.033, 07.094, 07.112 and 07.140] 
and accordingly these substances can be evaluated through the Procedure in this revision. Three of 
these substances were evaluated by the JECFA at its 59th meeting in 2002 [FL-no: 07.033, 07.094 
and 07.112] and the fourth was evaluated by the JECFA at its 63rd meeting. Since in the previous 
version of this FGE (FGE.51Rev1) 20 substances were discussed, the present revision will address 24 
flavouring substances.  
The Panel concluded that the 24 substances in the JECFA flavouring groups of alicyclic ketones, 
secondary alcohols and related esters and monocyclic and bicyclic secondary alcohols, ketones and 
related esters are structurally related to the group of secondary alicyclic saturated and unsaturated 
alcohols, ketones and esters with secondary alicyclic alcohol moieties evaluated by EFSA in Flavouring 
Group Evaluation 09, Revision 6 (FGE.09Rev6) (EFSA CEF Panel, 2015b). 
The chemical identity of [FL-no: 07.033] could not be unambiguously confirmed. Therefore the Panel 
could not consider the JECFA evaluation of this substance. The current revision of FGE.51 will consider 
only the safety of 23 JECFA-evaluated substances. 
For all 23 substances considered in this FGE, the Panel concluded that either they did not raise a 
concern with respect to genotoxicity, or that concerns with respect to genotoxicity due to the 
presence of a structural alert for this could be ruled out, based on experimental data. 
The Panel agrees with the application of the Procedure as performed by the JECFA for the 23 
substances considered in this FGE. 
For 23 JECFA evaluated alicyclic ketones, secondary alcohols and related esters [FL-no: 02.209, 
07.034, 07.035, 07.045, 07.094, 07.095, 07.098, 07.112, 07.126, 07.129, 07.140, 07.148, 07.149, 
07.172, 07.179, 07.180, 07.257, 09.027, 09.140, 09.160, 09.230, 09.464 and 09.930] the Panel 
agrees with the JECFA conclusion ‘no safety concern at estimated levels of intake as flavouring 
substance’ based on the MSDI approach. 
In order to determine whether the conclusion for the JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications: Adequate 
specifications including complete purity criteria and identity tests are available for 21 JECFA-evaluated 
substances. For [FL-no: 07.094 and 07.112] information on the solubility in water and ethanol is 
missing and therefore the conclusions on the named substance cannot be applied to the materials of 
commerce that correspond to these two FL-numbers. For substance [FL-no: 07.033] unambiguous 
information with respect to the chemical identity should be provided.  
For all substances evaluated through the Procedure use levels are needed to calculate the modified 
theoretical added maximum daily intake (mTAMDIs) in order to identify those flavouring substances 
that need more refined exposure assessment and to finalise the evaluation. 
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1. Introduction  
1.1. Background and Terms of Reference as provided by the requestor 
The use of flavouring is regulated under Regulation (EC) No 1334/20081 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of article 9(a) of this Regulation an evaluation and 
approval are required for flavouring substances. 
The Union List of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012.2 The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000.3 
On 25 November 2010, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids adopted an opinion on Flavouring Group Evaluation 212, Revision 1 (FGE.212Rev1): 
 α, β-unsaturated alicyclic ketones and precursors from chemical subgroup 2.6 of FGE.19.4 
The Panel concluded that the argumentation of Industry to expand its conclusion for the six-carbon 
ring members of subgroup 2.6 also to the cyclopentenyl derivatives in this subgroup [FL-no: 07.033, 
07.094, 07.112 and 07.140] was considered too limited, given the lack of support from experimental 
data. Therefore, additional genotoxicity tests are still required for the representative substance [FL-
no: 07.112] already chosen by the Panel. Alternatively, a more thorough explanation (physico-
chemical parameters; experimental underpinning) of the proposed similar reactivity of six- and five-
membered ring substances should be provided by Industry. 
The requested data have been submitted by the applicant. 
In addition, the flavouring substance [FL-no: 07.219], trans-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-
one, was put in FGE.212 (former FGE.19, subgroup 2.6b: α, β−unsaturated aldehydes and ketones 
and precursors) because of its structure relationship with this group. Although the substance as such 
is not mentioned in the data submitted by the applicant, the submitted data are likely to be relevant 
for [FL-no: 07.219] as well. 
Therefore, this request covers as well the re-evaluation of trans-3-methyl-2-(2-pentenyl)-2-
cyclopenten-1-one [FL-no: 07.219]. 
1.1.1. Terms of Reference as provided by the European Commission 
The European Commission requests the European Food Safety Authority (EFSA) to finalise its 
safety assessment of these flavouring substances in accordance with Commission Regulation (EC) 
No 1565/2000. 
1.2. Interpretation of the Terms of Reference 
The additional flavouring substances, isojasmone [FL-no: 07.033], 3-methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-one [FL-no: 07.094], 3-methyl-2-cyclopenten-1-one [FL-no: 07.112] and 3-
methyl-2-pentylcyclopent-2-en-1-one [FL-no: 07.140] were first allocated to FGE.212Rev2 for 
evaluation with respect to genotoxicity. Based on the new genotoxicity data submitted, the Panel 
concluded in FGE.212Rev3 that these four flavouring substances do not give rise to concern with 
respect to genotoxicity and can accordingly now be evaluated through the Procedure in FGE.51rev2. 
  
                                                          
1  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
2  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the 
list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, 
introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing 
Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1-161. 
3  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation 
programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
4  EFSA Journal 2011;9(3):1923 
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2. Data and Methodologies  
2.1. Description of key aspects of the evaluation methodology 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), hereafter named the ‘EFSA Procedure’. This 
Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999), which has been 
derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the ‘JECFA 
Procedure’. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring substances 
are of no safety concern at their estimated levels of intake, whether additional data are required or 
whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
2.1.1. Intake 
In its evaluation, the Panel as a default uses the ‘Maximised Survey-derived Daily Intake’ (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ‘how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods’ (JECFA, 2006). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an 
estimate of the daily intakes per person using a ‘modified theoretical added maximum daily intake’ 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on use 
levels in order to finalise the evaluation. 
2.1.2. Threshold of 1.5 µg/person per day (step B5) used by the JECFA 
The JECFA uses the threshold of concern of 1.5 µg/person per day as part of the evaluation 
procedure: 
‘The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended 
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that the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (‘Do the condition of 
use result in an intake greater than 1.5 µg per day?’)’ (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
2.1.3. Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in 
vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
2.1.4. Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different Opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
2.1.5. Structural relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
2.2. History of the evaluation of the substances in the present FGE 
At its 59th meeting the JECFA evaluated a group of 25 flavouring substances consisting of alicyclic 
ketones, secondary alcohols and related esters. Two substances were not in the Register, and 10 are 
 α, β-unsaturated ketones or precursors for such which have been considered together with other 
 α, β-unsaturated substances. The remaining 13 flavouring substances have originally been considered 
by EFSA in the FGE.51 (EFSA, 2008a). 
The first revision of FGE.51, FGE.51Rev1 included the consideration of seven additional substances 
[FL-no: 07.034, 07.035, 07.098, 07.126, 07.129, 07.172 and 09.930] (EFSA CEF Panel, 2012). Six of 
these additional substances [FL-no: 07.034, 07.035, 07.098, 07.126, 07.129 and 07.172] are 
 α, β-unsaturated ketones originally allocated to FGE.211 and FGE.212. The seventh substance [FL-no: 
09.930] is a precursor for such ketones originally allocated to FGE.211. The substances have been 
considered with respect to genotoxicity (EFSA CEF Panel, 2011a; 2011b) and the Panel concluded that 
the data available did rule out the concern for genotoxicity and accordingly the substances can be 
evaluated through the Procedure. Since the publication of FGE.51, the EU production volume has been 
provided for the substance, [FL-no: 09.230] for which the evaluation could not be finalised in the 
previous version of this FGE, due to lack of these data. Based on the submitted EU production volume 
the substance was evaluated in FGE.965 (EFSA CEF Panel, 2011c), but the information was also 
included in FGE.51. Finally, information on the stereoisomeric composition were provided for four 
substances [FL-no: 02.209, 07.045, 07.095 and 07.257] and composition of mixture for one substance 
[FL-no: 07.095] since the previous version of FGE.51 (EFFA, 2012). A search in open literature for the 
seven new substances did not provide any further data on toxicity or metabolism. 
The present revision of FGE.51, FGE.51Rev2 includes the consideration of four additional substances 
isojasmone [FL-no: 07.033], 3-methyl-2-(pent-2(cis)-enyl)cyclopent-2-en-1-one [FL-no: 07.094], 
3-methyl-2-cyclopenten-1-one [FL-no: 07.112] and 3-methyl-2-pentylcyclopent-2-en-1-one [FL-no: 
07.140].  
                                                          
5 Consideration of 88 flavouring substances considered by EFSA for which EU production volumes / anticipated production 
volumes have been submitted on request by DG SANCO. 
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Table 1:  Revisions of FGE.51  
FGE Opinion 
adopted by 
EFSA 
Link No. of 
candidate 
substances 
FGE.51 16 May 2007 http://www.efsa.europa.eu/en/efsajournal/doc/855.pdf 13 
FGE.51Rev1 22 March 2012 http://www.efsa.europa.eu/en/efsajournal/doc/2636.pdf 20 
FGE.51Rev2 3 December 2015 http://www.efsa.europa.eu/en/efsajournal/doc/4338.pdf 24 
 
The substances have been considered with respect to genotoxicity in FGE.212 Revision 3 (EFSA CEF 
Panel, 2015a) and the Panel concluded that the data available did rule out the concern for 
genotoxicity and accordingly the substances can be evaluated through the Procedure. A search in 
open literature for these four substances did not provide any further data on toxicity or metabolism. 
2.3. Presentation of the substances in the JECFA flavouring group 
2.3.1. Description 
Status 
The JECFA has evaluated a group of 25 flavouring substances consisting of alicyclic ketones, 
secondary alcohols and related esters at the 59th meeting in 2002 (JECFA, 2005) and a group of 32 
monocyclic and bicyclic secondary alcohols, ketones and related esters at the 63rd meeting in 2004 
(JECFA, 2005). 
EFSA Considerations 
From the group evaluated by JECFA at its 59th meeting in 2002, two of the JECFA-evaluated 
substances are not in the Register (4-methyl cyclohexanone (JECFA no: 1104) and (E)-2-(2-octenyl) 
cyclopentanone (JECFA no: 1116)). 
Of the remaining 23 substances, ten are α, β-unsaturated ketones or precursors for such. Seven of 
these [FL-no: 07.034, 07.035, 07.098, 07.126, 07.129, 07.172 and 09.930] have been considered with 
respect to genotoxicity in FGE.211 (EFSA CEF Panel, 2011a) and FGE.212Rev1 (EFSA CEF Panel, 
2011b), and the Panel concluded that the data available did rule out the concern for genotoxicity and 
accordingly the seven substances can be evaluated through the Procedure. For the remaining three 
 α, β−unsaturated substances [FL-no: 07.033, 07.094 and 07.112] considered with respect to 
genotoxicity in FGE.212Rev1, a final conclusion of genotoxic properties could not be reached and 
additional data were requested. These data were submitted and evaluated in FGE.212Rev3 (EFSA CEF 
panel, 2015a) and the Panel concluded that the data available did rule out the concern for 
genotoxicity and accordingly the three substances can be evaluated through the Procedure. 
From the group evaluated by JECFA at its 63rd meeting in 2004, three of the JECFA-evaluated 
substances are not in the Register (α-isomethylionyl acetate (JECFA no: 1410), d,l-Menthol(±)-
propylene glycol carbonate (JECFA no: 1413) and l-Monomenthyl glutarate (JECFA no: 1414)). Of the 
remaining 29 JECFA evaluated substances, 25 substances are considered by EFSA in other FGEs (in 
FGE.56, FGE.56, FGE.73 and FGE.87), one is evaluated in a separate EFSA Opinion (EFSA, 2008b) and 
two are no longer supported by Industry as flavouring substances in Europe (cycloheptadec-9-en-1-
one (JECFA no: 1401, former FL-no: 07.110) and 3-methylcyclopentadecan-1-one (JECFA no: 1402, 
former FL-no: 07.111). The one remaining substance, [FL-no: 07.140] was considered with respect to 
genotoxicity in FGE.212Rev3 (EFSA CEF panel, 2015a) and the Panel concluded that the data available 
did rule out the concern for genotoxicity. Accordingly the substance can be evaluated through the 
Procedure.  
This consideration will therefore deal with 24 JECFA-evaluated substances. 
The Panel concluded that the 24 substances in the JECFA flavouring groups of alicyclic ketones, 
secondary alcohols and related esters and monocyclic and bicyclic secondary alcohols, ketones and 
related esters are structurally related to the group of secondary alicyclic saturated and unsaturated 
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alcohols, ketones and esters with secondary alicyclic alcohol moieties evaluated by EFSA in Flavouring 
Group Evaluation 09, Revision 6 (FGE.09Rev6) (EFSA CEF Panel, 2015b). 
2.3.2. Isomers 
Status 
Six of the substances have one chiral centre [FL-no: 07.045, 07.129, 07.172, 07.179, 07.180 and 
07.257] and four substances have two or more chiral centres [FL-no: 02.209, 07.035, 07.095 and 
09.930]. Three substances have possibility for cis/trans isomerism [FL-no: 07.034, 07.094 and 
07.257]. For substance [FL-no: 07.033] originally information was provided that this substance 
consists of a mixture of isomers (see Table 2). Upon a request for further information with respect to 
the precise chemical composition and configuration of this material additional information was 
submitted (EFFA, 2015). However, this additional information did not result in a better 
characterisation of [FL-no: 07033]. Therefore the Panel concluded that for substance [FL-no: 07.033] 
the information on identity and composition is inadequate (e.g. chemical structures and CAS numbers 
provided are contradictory). 
EFSA Considerations 
Adequate information on isomeric composition is available for all substances, except for one 
substance, [FL-no: 07.033] for which the chemical identity cannot be unambiguously be stated. 
2.3.3. Specifications 
Status 
The JECFA specifications are available for all 24 substances (JECFA, 2002). See Table 2. 
EFSA Considerations 
The available specifications are considered adequate for all substances, except for [FL-no: 07.033, 
07.094 and 07.112]. For [FL-no: 07.094 and 07.112] information on the solubility in water and 
ethanol is missing. For substance [FL-no: 07.033] the chemical identity cannot be confirmed. As a 
consequence, the JECFA evaluation of [FL-no: 07.033] cannot be considered by the Panel. 
2.3.4. Intake estimations 
Status 
For all substances evaluated through the JECFA Procedure intake data are available for the EU, see 
Table 11. 
EFSA Considerations 
Tonnage data are available for the EU allowing calculation of the intake estimates (MSDI). The Panel 
noted that since no use levels were submitted, mTAMDI values cannot be calculated. 
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Table 2:  Summary of specification data for substances evaluated by the JECFA (JECFA, 2002) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA 
no 
CoE 
no 
CAS 
no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility(a) 
Solubility 
in 
ethanol(b) 
Boiling 
point, °C (c) 
Melting 
point, °C 
ID test 
Assay 
minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
EFSA comments 
02.209 
1099 
3,3,5-
Trimethylcyclohexan-1-ol 
OH
 
3962 
 
116-
02-9 
Solid 
C9H18O 
142.24 
Insoluble 
Soluble 
193-196 
30-34 
IR MS 
98% 
n.a. 
n.a. 
Racemate  
(EFFA, 2010). 
07.033 
1115 
Isojasmone  
 
3552 
167 
11050-
62-7 
Liquid 
C11H16O 
 164.24 
Insoluble  
1 mL in 1mL 
 
144 (13 hPa) 
 
NMR 
95% 
1.472-1.477 
0.917-0.924 
CAS Nr in Register 
refers to 2-
cyclopenten-1-one, 2-
methyl-3-(2-penten-1-
yl)-. Additional 
information indicates 
that this substance 
consists of 2-hexyl-2-
cyclopent-1-one + 2-
pentyl-2-cyclohexen-
1-one. However the 
CAS Nr provided do 
not correspond with 
these structures. 
Therefore, this 
substance will not be 
further evaluated in 
the current revision of 
this FGE. 
07.034 
1106 
2-
Hexylidenecyclopentan-
1-one 
O
 
2573 
167 
17373-
89-6 
Liquid 
C11H18O 
166.26 
Insoluble 
Miscible 
240 
 
NMR 
98% 
1.477-1.484 
0.907-0.914 
Mixture E/Z (50/50) 
(EFFA, 2012). 
O
+
O
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FL-no 
JECFA-
no 
EU Register name Structural formula FEMA 
no 
CoE 
no 
CAS 
no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility(a) 
Solubility 
in 
ethanol(b) 
Boiling 
point, °C (c) 
Melting 
point, °C 
ID test 
Assay 
minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
EFSA comments 
07.035 
1111 
Tetramethyl 
ethylcyclohexenone 
(mixture of isomers) 
OO
29 % 68 %
+
 
3061 
168 
17369-
60-7 
Liquid 
C12H20O 
180.29 
Slightly 
soluble 
Miscible 
113-115 
 
NMR 
97% 
1.485-1.490 
0.927-0.934 
Mixture of 5-ethyl-
2,3,4,5-tetramethyl-2-
cyclohexen-1-one and 
5-ethyl-3,4,5,6-tetra-
methyl-2-cyclohexen-
1-one. The 
predominant 
constituent is 5-ethyl-
3,4,5,6-tetramethyl-2-
cyclohexen-1-one. 
Mixture of 
diastereoisomers in 
approximately equal 
ratios (EFFA, 2012). 
07.045 
1108 
2,2,6-
Trimethylcyclohexanone 
O
 
3473 
686 
2408-
37-9 
Liquid 
C9H16O 
140.23 
Insoluble 
Miscible 
178-179 
 
NMR 
99% 
1.443-1.449 
0.900-0.907 
Racemate  
(EFFA, 2010). 
07.094 
1114 
3-Methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-
one 
O
 
3196 
11786 
488-
10-8 
Liquid 
C11H16O 
164.25 
 
 
248 
 
NMR 
98% 
1.495-1.501 
0.942-0.948 
According to JECFA: 
Min. assay value is ‘98 
cis’. 
07.095 
1109 
2-(sec-
Butyl)cyclohexanone 
O
 
3261 
11044 
14765-
30-1 
Liquid 
C10H18O 
154.25 
Insoluble 
Miscible 
76-78 
 
NMR 
94% 
1.454-1.461 
0.911-0.917 
Mixture of 
diastereoisomers, 
approximately 25% of 
each (EFFA, 2012). 
Min assay 94% 
secondary comp. 2-
isobutyl 
cyclohexanone 2-
2.5% (EFFA, 2010).  
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FL-no 
JECFA-
no 
EU Register name Structural formula FEMA 
no 
CoE 
no 
CAS 
no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility(a) 
Solubility 
in 
ethanol(b) 
Boiling 
point, °C (c) 
Melting 
point, °C 
ID test 
Assay 
minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
EFSA comments 
07.098 
1107 
3-Methylcyclohex-2-en-1-
one 
O
 
3360 
11134 
1193-
18-6 
Liquid 
C7H10O 
110.16 
Miscible 
Miscible 
199-200 
 
NMR 
98% 
1.490-1.498 
0.967-0.972 
 
 
07.112 
1105 
3-Methyl-2-cyclopenten-
1-one 
O
 
3435 
11137 
2758-
18-1 
Liquid 
C6H8O 
96.12 
 
 
74 (20 hPa) 
 
NMR 
98% 
1.485-1.491 
0.968-0.975 
 
 
07.126 
1112 
3,5,5-Trimethylcyclohex-
2-en-1-one 
O
 
3553 
11918 
78-59-
1 
Liquid 
C9H14O 
138.21 
Slightly 
soluble 
Miscible 
213-215 
 
NMR 
97% 
1.474-1.481 
0.919-0.927 
 
 
07.129 
1113 
3-Methyl-5-
propylcyclohex-2-en-1-
one 
O
 
3577 
 
3720-
16-9 
Liquid 
C10H16O 
152.23 
Insoluble 
Miscible 
242-244 
 
NMR 
95% 
1.481-1.486 
0.924-0.928 
Racemate  
(EFFA, 2012) 
07.140 
1406 
3-Methyl-2-
pentylcyclopent-2-en-1-
one 
O
 
3763 
 
1128-
08-1 
Liquid 
C11H18O 
166.26 
Very slightly 
soluble 
Soluble 
79 (0.2 hPa) 
 
NMR 
99% 
1.676-1.682 
0.911-0.917 
 
 
07.148 
1100 
Cyclohexanone O
 
3909 
11047 
108-
94-1 
Liquid 
C6H10O 
98.14 
 
Miscible 
154-156 
 
IR NMR MS 
99% 
1.447-1.453 
0.947-0.950 
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FL-no 
JECFA-
no 
EU Register name Structural formula FEMA 
no 
CoE 
no 
CAS 
no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility(a) 
Solubility 
in 
ethanol(b) 
Boiling 
point, °C (c) 
Melting 
point, °C 
ID test 
Assay 
minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
EFSA comments 
07.149 
1101 
Cyclopentanone O
 
3910 
11050 
120-
92-3 
Liquid 
C5H8O 
84.12 
 
Miscible 
130-131 
 
IR NMR MS 
99% 
1.432-1.438 
0.950-0.960 
 
 
07.172 
1110 
4-Isopropylcyclohex-2-
en-1-one 
O
 
3939 
11127 
500-
02-7 
Liquid 
C9H14O 
138.21 
Insoluble 
Miscible 
198 
 
NMR 
97% 
1.481-1.490 
0.930-0.950 
Racemate  
(EFFA, 2012). 
07.179 
1102 
2-Methylcyclohexanone O
 
3946 
 
583-
60-8 
Liquid 
C7H12O 
112.17 
Insoluble 
Miscible 
163-163 
 
IR NMR MS 
96% 
1.444-1.450 
0.924-0.926 
Racemate. 
07.180 
1103 
3-Methylcyclohexanone O
 
3947 
 
591-
24-2 
Liquid 
C7H12O 
112.17 
Insoluble 
Miscible 
169-170 
 
IR NMR MS 
97% 
1.440-1.450 
0.914-0.919 
Racemate. 
07.257 
1117 
2-(3,7-Dimethyl-2,6-
octadienyl) 
cyclopentanone 
O 3829 
 
68133-
79-9 
Liquid 
C15H24O 
220.35 
Insoluble 
Miscible 
130 (4 hPa) 
 
NMR MS 
95% 
1.482-1.489 
0.911-0.916 
Racemic mixture of 
(E)- and (Z)-isomers 
(EFFA, 2010). The 
double bond occurs 
mainly as E-isomer (at 
least 80% E and max 
20% Z)  
(EFFA, 2012). 
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FL-no 
JECFA-
no 
EU Register name Structural formula FEMA 
no 
CoE 
no 
CAS 
no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility(a) 
Solubility 
in 
ethanol(b) 
Boiling 
point, °C (c) 
Melting 
point, °C 
ID test 
Assay 
minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
EFSA comments 
09.027 
1093 
Cyclohexyl acetate 
O
O
 
2349 
217 
622-
45-7 
Liquid 
C8H14O2 
142.19 
Insoluble 
Miscible 
175-177 
 
NMR 
98% 
1.436-1.443 
0.971-0.978 
 
 
09.140 
1097 
Cyclohexyl propionate 
O
O
 
2354 
421 
6222-
35-1 
Liquid 
C9H16O2 
156.23 
Insoluble 
Miscible 
193 
 
NMR 
97% 
1.439-1.446 
0.969-0.974 
 
09.160 
1095 
Cyclohexyl formate 
O
O
 
2353 
498 
4351-
54-6 
Liquid 
C7H12O2 
128.17 
Insoluble 
Miscible 
162-163 
 
NMR 
97% 
1.439-1.445 
1.052-1.060 
 
09.230 
1094 
Cyclohexyl butyrate 
O
O
 
2351 
2082 
1551-
44-6 
Liquid 
C10H18O2 
170.25 
Practically 
insoluble 
Miscible 
212 
 
NMR 
98% 
1.439-1.451 
0.953-0.959 
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FL-no 
JECFA-
no 
EU Register name Structural formula FEMA 
no 
CoE 
no 
CAS 
no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility(a) 
Solubility 
in 
ethanol(b) 
Boiling 
point, °C (c) 
Melting 
point, °C 
ID test 
Assay 
minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
EFSA comments 
09.464 
1096 
Cyclohexyl isovalerate 
O
O
 
2355 
459 
7774-
44-9 
Liquid 
C11H20O2 
184.28 
Insoluble 
Miscible 
58-62 
 
NMR 
95% 
1.439-1.445 
0.945-0.952 
 
09.930 
1098 
Cyclohexyl, 2-methylene-
5-(1-methylethenyl) 
acetate 
O O
 
3848 
 
71660-
03-2 
Liquid 
C12H18O2 
194.27 
Insoluble 
Miscible 
77-79 (0.1 
hPa) 
 
IR NMR MS 
95% 
1.473-1.479 
0.964-0970 
Mixtures of 
diastereoisomers 
(25% of each)  
(EFFA, 2012). 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95% ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. 
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2.4. Genotoxicity data 
2.4.1. Genotoxicity studies – Text taken6 from the JECFA (JECFA, 2003) 
Genotoxicity data in vitro 
Five of the 137 alicyclic ketones, secondary alcohols and related esters have been tested for 
genotoxicity. Overall, negative results were reported in the standard assay for reverse mutation when 
various strains of Salmonella typhimurium (TA98, TA100, TA1535, TA1537 and TA1538) were 
incubated with up to 10,000 µg/plate of cyclohexanone [FL-no: 07.148], 2.5–2500 µg/plate of 
cyclopentanone [FL-no: 07.149] or up to 4200 µg/plate of 2,2,6-trimethyl cyclohexanone [FL-no: 
07.045] with or without metabolic activation (Florin et al., 1980; Haworth et al., 1983). In another test 
for reverse mutation with S. typhimurium TA98, TA100, TA1535 and TA1537 (only an abstract), 
cyclohexanone was reported to produce ‘a large number of revertants’ in TA98, with no further 
elaboration and no results for the other strains. The concentrations and test conditions used were not 
specified (Massoud et al., 1980).  
Both cyclohexyl acetate [FL-no: 09.027] and cyclohexyl butyrate [FL-no: 09.230] gave negative results 
for mutation in Bacillus subtilis M45 (rec–) and H17 (rec+) (Oda et al., 1979; Yoo, 1986). Positive 
results were reported with cyclohexanone in an assay for forward mutation assay in B. subtilis 
(Massoud et al., 1980); however, as previously stated, no concentrations or test conditions were 
reported in the abstract. 
Cyclohexanone [FL-no: 07.148] at concentrations up to 980 µg/mL induced chromosomal aberrations 
in human lymphocytes with or without metabolic activation (Collin, 1971; Lederer et al., 1971; 
Dyshlovoi et al., 1981). It did not induce chromosomal aberrations in Chinese hamster ovary cells at a 
concentration of 7.5 µl/mL, with or without metabolic activation (Aaron et al., 1985). In an assay for 
sister chromatid exchange, cyclohexanone at a concentration of 7.5 µl/mL gave weakly positive results 
in Chinese hamster ovary cells in the absence of metabolic activation and negative results in the 
presence of metabolic activation (Aaron et al., 1985). 
Genotoxicity data in vivo 
When cyclohexanone [FL-no: 07.148] was fed to adult Drosophila melanogaster for 3 days, no 
mutations were observed (Goncharova, 1970; Wild et al., 1983; Foureman et al., 1994). 
Conclusion 
Cyclohexyl acetate, cyclohexyl butyrate, cyclopentanone and 2,2,6-trimethyl cyclohexanone gave 
negative results in assays for genotoxicity in vitro. The results reported for the genotoxicity of 
cyclohexanone are conflicting. Most of the assays were conducted before 1986, when the pH and ionic 
strength of test media were often not adequately maintained. Mammalian cells in situ rely on complex 
regulatory mechanisms to maintain homeostatic conditions, and those in culture are not equipped to 
respond to environmental changes; therefore, it is important that the culture media used in 
mammalian cell assays be maintained at a pH of approximately 6.8–7.5. A lower pH or changes in 
osmolality due to the test agents can give rise to false-positive results, especially when metabolic 
activation systems are added. Acidity facilitates the breakdown of the components of such systems 
into mutagenic agents (Brusick, 1986). 
The equivocal results of the assays for genotoxicity with cyclohexanone in vitro can be interpreted in 
terms of physiochemical properties. Compounds that are structurally similar to cyclohexanone have 
excellent membrane permeability and hydrogen bonding potential (Slater, 1963; Slater, 1967; 
Moreland, 1994). When cyclohexanone and related substances are tested in vitro, they may induce 
membrane expansion, leading to multiple effects on membrane-related processes. Membrane 
expansion may increase cell volume and lipid storage vacuoles, block ionic conductance channels, limit 
                                                          
6 The text is taken verbatim from the indicated reference source, but text related to substances not included in FGE.51 has 
been removed. 
7 The genotoxicity data available for the new substances evaluated by JECFA and evaluated by EFSA with respect to 
genotoxicity concern due to the  α, β−unsaturated structures are summarised in Sections 3.3. and 3.4. 
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the availability of ATP and alter ion fluxes and metabolite distribution between the cytoplasm and 
organelles. Given these physiochemical properties, it is highly unlikely that any consistent pattern of 
genotoxicity would result from a battery of assays in bacterial and mammalian cells. 
Overall, the tests for genotoxicity yielded mainly negative results. Positive results were reported in 
mammalian cells at cytotoxic concentrations, usually in the absence of biotransformation enzymes. 
The in vivo assay result was negative. 
For a summary of in vitro/in vivo genotoxicity data considered by JECFA see Table 3. 
2.4.2. Genotoxicity studies – Text taken8 from EFSA FGE.09Rev6 (EFSA CEF 
Panel, 2015b) 
Genotoxicity data in vitro / in vivo 
Genoxicity data are available for only three candidate substances cyclohexanol [FL-no: 02.070], 
cyclopentanol [FL-no: 02.135], methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] and for 
nine supporting substances and one structurally related substances.  
Cyclohexanol [FL-no: 02.070] was not genotoxic in two Ames tests and in an in vivo micronucleus 
assay, which are all considered as valid studies. However, the results of the in vivo study are of 
limited relevance, due to the lack of evidence that the substance did reach the bone marrow. 
Inconclusive results were reported in an in vitro chromosomal aberration assay with human leukocytes 
and negative results were reported in a dominant lethal mutations assay with Drosophila 
melanogaster; both studies were considered inadequate. Cyclopentanol [FL-no: 02.135] was studied in 
a valid Ames test. No mutagenicity was found. 
A battery of in vitro and in vivo genotoxicity studies were conducted on methyl 3-oxo-2-pentyl-1-
cyclopentylacetate [FL-no: 09.520] including valid negative reverse mutation tests in Escherichia coli 
(Wagner and Klug, 2000) and Salmonella typhimurium (Thompson, 2000). 
In a mouse lymphoma test, pre-dating GLP, a more than 2-fold increase of the mutant frequency over 
the solvent treated control values was found at the highest tested cytotoxic concentration of 300 
µg/mL in the presence of metabolic activation, and at the two highest tested cytotoxic concentrations 
of 200 and 300 µg/mL in the absence of metabolic activation. Only limited documentation is provided 
in the study report; together with the fact that several cultures were infected and a lack of a 
confirmatory test, it is impossible to assess the reliability of these results (Ross and Harris, 1979).  
No induction of forward mutations at the TK locus in L5178Y mouse lymphoma cells were found in a 
study performed in compliance with the current OECD test guidelines, both in the absence and in the 
presence of metabolic activation, up to and including cytotoxic concentrations (Cifone, 2001).  
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate was tested in a bone marrow micronucleus test in mice 
following a single intraperitoneal administration of 0, 280, 560 or 1120 mg/kg bw in corn oil. The 
study was performed in compliance with the current OECD test guidelines. The two highest doses 
chosen induced clear signs of toxicity; slight reductions (up to 12%) in the ratio of polychromatic 
erythrocytes to total erythrocytes were found, indicating that the test material had reached the target 
cells. No increase in micronucleated cells was found in the groups treated with the test material. The 
positive control induced the expected increases (Gudi and Krsmanovic, 1998). 
In an Unscheduled DNA Synthesis (UDS) study, the ability of methyl 3-oxo-2-pentyl-1-
cyclopentylacetate to induce DNA repair was studied in isolated rat hepatocytes after administration in 
vivo. The study was performed in compliance with the current OECD Guideline 486 (OECD, 1997). 
Methyl 3-oxo-2-pentyl-1-cyclopentylacetate was administered to male Sprague-Dawley CD rats by 
intra-peritoneal injection in doses of 333.3 and 1000 mg/kg bw (the latter dose was the maximum 
tolerated dose) followed by liver perfusion at 2 or 16 h after dosing. No marked increase in the 
incidence of UDS was observed at either dose level or perfusion time. Statistically significant 
differences were revealed in the positive control groups when compared to the negative control group 
and the test article (Durward, 2001). 
                                                          
8 The text is taken verbatim from the indicated reference source. 
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Genotoxicity data are available for nine supporting substances [FL-no: 02.015, 02.062, 07.148, 
07.176, 09.027, 09.215, 09.230, 07.149 and 07.045]. 
Cyclohexanone [FL-no: 07.148], structurally related to the alicyclic ketones and secondary alcohols in 
this FGE, was not mutagenic in an Ames test, considered to be valid. Negative and positive results 
were reported in several other in vitro studies at gene and chromosomal level, as well as a negative 
result in a sex-linked recessive lethal mutations in D. melanogaster. However, these studies were 
considered inadequate.  
Menthol [FL-no: 02.015] gave negative results in an in vitro alkaline elution assay for detecting DNA 
single strand breaks in rat hepatocytes. With the same substance equivocal results in an in vivo host 
mediated mutation assay were observed at high dose levels and negative results in several Ames 
tests, a TK+/- mouse lymphoma assay, sister chromatid exchange (SCE) tests in Chinese hamster 
ovary (CHO) cells and human lymphocytes, and chromosomal aberration assays with human 
embryonic lung cells, human lymphocytes and CHO cells. Negative results were also reported in two in 
vivo micronucleus and chromosomal aberration assays. However, the results of these studies have a 
limited relevance, due to the lack of bone marrow toxicity. In addition, an in vivo dominant lethal 
assay was available, from which also negative results were obtained. trans-Menthone [FL-no: 07.176] 
was genotoxic in an Ames test and in a somatic mutation and recombination test (SMART) with 
Drosophila. The observed effects were not very pronounced. Further, trans-menthone is easily 
converted to menthol, which is estimated to be overall negative in genotoxicity tests. 
Carveol and carvyl acetate [FL-no: 02.062 and 09.215] were tested in Ames test at various doses from 
10 - 560 µg/plate in the Salmonella typhimurium strains TA97, TA98, TA100, TA1535 and TA1537 
with and without S9 mix in dimethyl sulphoxide. Positive and negative controls were used. No 
mutagenicity was observed. (Mortelmans et al., 1986). 
Conclusion on genotoxicity  
For five of the candidate substances [FL-no: 07.109, 07.202, 07.219, 07.255 and 09.870] it has been 
concluded that a concern for genotoxicity, indicated by the presence of a structural alert, could be 
ruled out based on experimental data for supporting substances. 
Only for three of the candidate substances some genotoxicity data are available, and for these three 
mainly negative results were obtained. For the supporting substances mainly negative, but also some 
positive results were obtained. The positive results were obtained in poorly reported tests, or in tests, 
which are difficult to interpret with respect to their relevance for genotoxicity.  
Overall, the genotoxic potential of this group of flavouring substances cannot be fully assessed. 
However, the data available do not indicate a genotoxic potential and therefore do not preclude their 
evaluation via the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA see Tables 4 and 5. 
2.4.3. Genotoxicity studies – Text taken9 from EFSA FGE.211 (EFSA CEF Panel, 
2011a) 
The following text is relevant for two substances [FL-no: 07.034 and 09.930] in this revision of 
FGE.51. 
The Industry has submitted data concerning genotoxicity studies for the one representative substance 
for subgroup 2.5, 1(7),8-p-menthadien-2-yl acetate [FL-no: 09.930] (structurally related to 1(7),8-p-
menthadien-2-one). 
In vitro data 
The newly available data comprise a bacterial reverse mutation assay and an in vitro micronucleus 
assay with human peripheral blood lymphocytes. The genotoxicity assays have been performed on a 
commercial mixture of the representative substance 1(7),8-p-menthadien-2-yl acetate and a positional 
isomer, carvyl acetate. Carvyl acetate can be hydrolysed to carvone, which has been evaluated by 
                                                          
9 The text is taken verbatim from the indicated reference source 
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EFSA in FGE.212 (EFSA, 2009) and NTP (NTP, 1990a) as non-genotoxic. The highest concentration of 
d-carvone that could be tested without cytotoxicity was 333 µg/plate (Mortelmans et al., 1986), i.e. 
the cytotoxicity was in the same range as observed for the mixture of 1(7),8-p-menthadien-2-yl 
acetate/carvyl acetate. The Panel concluded that testing the commercial mixture of 1(7),8-p-
menthadien-2-yl acetate/carvyl acetate for genotoxicity allows the evaluation of the genotoxic 
potential of 1(7),8-p-menthadien-2-yl acetate. The concentrations reported in Table 6 are for the 
mixture of substances. 
Bacterial Reverse Mutation Assay 
1(7),8-p-menthadien-2-yl acetate/carvyl acetate was tested for mutagenic activity according to OECD 
guideline 471 and in compliance with GLP (Beevers, 2010). The test material exhibited a marked 
toxicity as indicated by thinning of the background lawn, reduced revertant counts and complete 
killing of test bacteria. However, the Panel considered the remaining number of concentrations 
without signs of toxicity sufficient to draw a conclusion on mutagenicity in this system (for details see 
table 6).  
Overall, the Panel concluded that there was no evidence of mutagenic activity of 1(7),8-p-
menthadien-2-yl acetate/carvyl acetate at concentrations up to those causing bactericidal effects. 
In vitro Micronucleus Test 
1(7),8-p-menthadien-2-yl acetate/carvyl acetate was tested for induction of micronuclei in human 
peripheral blood lymphocytes according to OECD guideline 487 and in compliance with GLP (Whitwell, 
2010). The Panel considered that acceptable levels of cytotoxicity as judged upon the replication index 
were achieved at the top concentrations (for details see Table 6).  
Overall, the Panel concluded that no evidence of chromosomal damage or aneuploidy was observed 
by increased levels of micronucleated binucleate cells (MNBN) in the presence or absence of S9 
metabolic activation. 
Discussion of Mutagenicity/Genotoxicity Data 
The commercial mixture of the representative substance 1(7),8-p-menthadien-2-yl acetate and a 
positional isomer, carvyl acetate was tested for all three genetic endpoints: gene mutations, structural 
and numerical chromosomal aberrations. The test material did not induce gene mutations in bacteria 
and was not clastogenic and/or aneugenic in mammalian cells in vitro. Although this commercial 
mixture was cytotoxic at high concentrations. the remaining concentrations without signs of toxicity 
provide a valid data set. 
Conclusion 
The in vitro genotoxicity data on the commercial mixture of the representative substance 1(7),8-p-
menthadien-2-yl acetate [FL-no: 09.930] and a positional isomer, carvyl acetate do not indicate 
genotoxic potential. Accordingly the four substances in FGE.211 (subgroup 2.5) would be of no safety 
concern with respect to genotoxicity. 
A summary of the in vitro genotoxicity data is given in Table 6. 
2.4.4. Genotoxicity studies – Text taken10 from EFSA FGE.212 (EFSA, 2009), 
FGE.212Rev1 (EFSA CEF Panel, 2011b) and FGE.212Rev3 (EFSA CEF 
Panel, 2015a) 
The following text is relevant for five substances [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 
07.126, 07.129, 07.140 and 07.172] in this revision of FGE.51. 
  
                                                          
10 The text is taken verbatim from the indicated reference source, but text related to substances not included in FGE.51 has 
been removed. 
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For substances evaluated in FGE.212 and FGE.212Rev1 
For tetramethyl ethylcyclohexenone (mixture of isomers) [FL-no: 07.035] one in vitro and one in vivo 
study are available and have been evaluated. Seven in vitro and three in vivo studies are available for 
3,5,5 trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone). 
Negative results were also observed with tetramethyl ethylcyclohexenone [FL-no: 07.035] in bacteria, 
in a sex-linked recessive lethal mutation assay in Drosophila (Wild et al., 1983) and in a mouse 
micronucleus assay (Wild et al., 1983); however, there was a mixture of isomers tested and the 
studies were only of limited validity. 3,5,5 Trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) 
did not induce gene mutations in bacteria but it induced mutations in mammalian cells in a mouse 
lymphoma TK assay in the absence of metabolic activation (it was not tested in the presence of 
metabolic activation) (NTP, 1986). No mutations in the MLTK assay were observed in a study of 
O’Donoghue et al. (O’Donoghue et al., 1988) at comparable concentrations. Isophorone induced 
chromosomal aberrations in Chinese hamster lung fibroblasts with and without metabolic activation 
(Matsuoka et al., 1996) and sister chromatid exchanges (SCE) in CHO cells without metabolic 
activation (Gulati et al., 1989). Chromosomal aberrations have not been observed in two other studies 
(Gulati et al., 1989; NTP, 1986); however, the validity of the results was limited because the types of 
aberrations were not reported. Isophorone did not induce unscheduled DNA synthesis (UDS) in rat 
hepatocytes in vitro. In vivo, isophorone was tested negative in a sex-linked recessive lethal mutation 
assay in Drosophila (Foureman et al., 1994) and in two micronucleus assays in mice (McKee et al., 
1987; O’Donoghue et al., 1988). However, the Drosophila assay has only limited relevance and the 
micronucleus assays were of limited validity. 
Conclusion on genotoxicity from FGE.212 
Isophorone [FL-no: 07.126 (3,5,5-trimethylcyclohex-2-en-1-one)] is genotoxic in vitro and since there 
is some evidence of carcinogenicity in male rats and equivocal evidence of carcinogenicity in male 
mice and since a non-threshold mechanism could not be excluded based on the data currently 
available, the Panel concluded that additional data are required for isophorone in order to clarify 
whether genotoxicity occurs in vivo and whether there is a threshold for the effects observed in the 
target organs in the long-term bioassays. Therefore, an in vivo Comet assay in F344/N rats covering 
these target organs is required in addition to an in vivo bone marrow assay with oral application.  
Due to structural similarities and lack of data, the remaining substances cannot presently be evaluated 
through the Procedure [FL-no: 07.035, 07.098, 07.129 and 07.172]. Additional data on genotoxicity 
are requested for representative substances of this subgroup according to the opinion of the Panel on 
the Genotoxicity Test Strategy for Substances Belonging to Subgroups of FGE.19 (EFSA, 2008c) 
Data submitted from Industry in reply to request for additional genotoxicity data in FGE.212 
Honma et al. (Honma et al., 1999a; Honma et al., 1999b) found that isophorone did not clearly induce 
mutations in the mouse lymphoma assay (MLA) following 3 h treatments, but observed that it was 
mutagenic after 24 h treatments in the absence of S9. Although only graphs are plotted, it seems that 
increases in mutation frequency (MF) that exceeded the Global Evaluation Factor (GEF) occurred at 
around 1250–1500 µg/mL where toxicity (by relative survival) reached 70–90%. 
The NTP conducted a mouse bone marrow chromosomal aberration (CA) study on isophorone. Groups 
of 8 male B6C3F1 mice (larger group sizes than required by OECD) were dosed i.p. with isophorone at 
125, 250 and 500 mg/kg bw. The standard protocol for in vivo CA is not given on the NTP website 
(NTP, 1990b). However, based on Shelby and Witt (Shelby and Witt, 1995), animals should have been 
sampled at 17 h and, if negative, also at 36 h. The data on the NTP website are only for bone marrow 
sampled at 36 h. It is therefore possible that a 17 h sample was also taken, and found to be negative, 
but the data have not been posted. Fifty cells per animal were scored for CA and no increases in CA 
were seen. No measures of toxicity were recorded, but i.p. dosing should have guaranteed systemic 
exposure. The control CA frequency was normal (2.75%) and the positive control 
(dimethylbenzanthracene) produced a significant response in CA frequency.  
A DNA binding study was conducted in which F344‐rats and B6C3F1‐mice (the strains used in the NTP 
carcinogenicity study) were exposed to isophorone (Thier et al., 1990). Animals of both sexes were 
dosed once or five times by gavage with 500 mg/kg bw of unlabelled isophorone spiked with 
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[1,3,5‐14C]‐isophorone (specific activity: 52 mCi per mmol, 1.92 GBq per mmol). An additional group 
of acute dosed male rats received undiluted 14C‐isophorone for increased sensitivity. Rats and mice 
were maintained for 24 h in closed metabolic cages. Twenty-four h after exposure, livers and kidneys 
(the tumour target tissues) were removed from the animals. DNA was isolated through hydroxyapatite 
chromatography and radioactivity was measured by liquid scintillation counting. No positive controls 
were included. Also no untreated controls were included, but, except for the liver sample of one 
mouse in the five times dose group, radioactivity values were within 2σ of background (6 dpm). 
Radioactivity values therefore did not indicate significant attachment of radioactivity to DNA. From 
these results it can be concluded that neither isophorone nor its metabolites bind covalently to DNA. 
In addition, a report by Morishita et al. (Morishita et al., 1997) submitted to EPA (EPA, 1997), is 
relevant and appears to have been previously submitted only as an abstract. This study was designed 
to investigate whether isophorone and/or α2µ‐globulin11 might be involved in the induction of 
preputial gland tumours in F‐344 rats. A series of experiments was performed in order to study several 
parameters including: 
• binding of isophorone to DNA of kidney and preputial gland. Groups of 10 male rats were 
dosed by gavage with 500 mg/kg of [14C]‐isophorone (specific activity 14.65 mCi/mmol; 100 
µCi/animal). Positive control animals were dosed with 3H‐labeled methyl nitrosourea. 
• DNA adduct detection by 32P‐postlabeling in young adult male and female rats (7 per group) 
dosed by gavage with 0, 250 or 500 mg/kg isophorone for five days. 
Extraction of preputial gland and kidney DNA from rats treated with single 500 mg/kg labelled doses 
yielded no evidence of isophorone binding to DNA, whereas the positive control showed significant 
binding to DNA of preputial gland and kidney. These negative results with isophorone were confirmed 
in the 32P‐post labelling assays.  
Discussion of the additional data and conclusion 
Conflicting results were reported in two valid studies with the mouse lymphoma assay (MLA): one 
negative (O’Donoghue et al., 1988) and one positive (NTP, 1986) at comparable concentrations. 
Mixed results were also reported in two studies of limited validity: one negative (Honma et al., 1999a) 
and one positive (Honma et al., 1999b). Another negative result was reported in a study (McKee et 
al., 1987), the validity of which cannot be evaluated. In the light of the clearly negative results in two 
valid bacterial gene mutation tests (Ames test) and in a valid Sex Linked Recessive Lethal Mutations 
test (SLRL) in Drosophila, and taking into account the lack of specificity and high sensitivity of the 
MLA, overall the results presently available are considered of questionable relevance. The Panel 
agrees that isophorone demonstrates some genotoxic activity in vitro but that the new data 
demonstrate lack of clastogenicity in vivo. In addition, the new DNA-binding data from two separate 
studies provide convincing evidence that isophorone does not induce tumours via a genotoxic 
mechanism. On the basis of these data it may be argued that there is no need to perform further in 
vivo genotoxicity studies such as the Comet assay or bone marrow micronucleus test. Thus, based on 
the data available the Panel concluded in FGE.212Rev1 that there is no concern with respect to 
genotoxicity of isophorone. 
For substances evaluated in FGE.212Rev3 
In order to investigate the potential of 3-methyl-2-cyclopenten-1-one [FL-no: 07.112] to induce gene 
mutations in bacteria, an Ames test was performed according to OECD Test Guideline 471 (OECD, 
1997) and following Good Laboratory Practice (GLP) in five strains of S. typhimurium (TA98, TA100, 
TA1535, TA1537 and TA102) in the presence or absence of metabolic activation by S9-mix in two 
separate experiments. In Experiment 1 the ‘plate incorporation assay’ was applied, in Experiment 2 
treatment with S9-mix included a pre-incubation step (20 min at 37°C). Seven different concentrations 
of the test substance were tested using appropriate positive control chemicals and purified water as 
negative control. The highest concentration selected was 5000 µg /plate (range from 5 to 5000 µg/mL 
and from 80 to 5000 µg/mL in Experiment 1 and 2, respectively). All positive control chemicals 
                                                          
11 Since interaction with α2µ-globulin is not of direct relevance for the evaluation of genotoxic potential, this information is 
omitted from this study summary. 
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induced significant increases in revertant colony numbers, confirming the sensitivity of the tests and 
the efficacy of the S9-mix, while the negative controls were within the normal ranges. After treatment 
with 3-methyl-2-cyclopenten-1-one in Experiment 1 evidence of toxicity, in the form of diminished 
background bacterial lawn, was observed at 5000 µg/mL both in the presence and absence of S9-mix 
in all strains; in addition, strain TA98 showed toxicity also at 160, 500 and 1600 µg/mL. In most 
experimental points, at the same concentrations the number of revertant colonies was relatively low. 
In Experiment 2, toxicity was observed at 5000 µg/mL in all strains but TA102, both in the presence 
and absence of S9-mix (Bowen, 2014). 
No increase in revertant colony numbers was observed at any concentration tested in either the 
presence and absence of S9-mix. Therefore, it was concluded that 3-methyl-2-cyclopenten-1-one has 
no mutagenic activity under the conditions employed. 
The in vitro micronucleus assay was carried out according to the OECD Test Guideline 487 (OECD, 
2010) and following GLP. Duplicate cultures of human peripheral blood lymphocytes, prepared from 
the pooled blood of two female donors and stimulated with phytohaemagglutinin (PHA), were treated 
with purified water (negative control), 3-methyl-2-cyclopenten-1-one or appropriate positive controls 
(mitomycin C and noscapine as clastogenic and aneugenic chemicals, respectively, in the absence of 
S9-mix; cyclophosphamide as a clastogenic chemical in the presence of S9-mix). A single experiment 
was performed 48 h after mitogen stimulation, following two treatment schedules: 3 + 21 h in the 
presence and absence of S9-mix, and 24 + 0 h without S9-mix. Micronuclei were analysed at three 
concentrations (600, 800 and 962 µg/mL; the highest concentration is equivalent to 10mM) chosen on 
the basis of a preliminary cytotoxicity range-finder Experiment. Applying the 3 + 21 h treatment, the 
cultures were exposed to 3-methyl-2-cyclopenten-1-one for 3 h either in the presence or the absence 
of the S9-mix. In the 24 + 0 h treatment cultures were continuously exposed to 3-methyl-2-
cyclopenten-1-one for 24 h without the S9-mix. In all cases the cells were harvested 24 h after the 
beginning of treatment (i.e. 72 h after culture initiation). Four thousand binucleated cells per 
concentration were analysed. All positive control chemicals induced statistically significant increases in 
the frequency of micronucleated cells, confirming the sensitivity of the tests and the efficacy of the 
S9-mix, while the negative controls were within 95th percentile of the current observed historical 
vehicle control ranges. At any concentration tested both in the presence and absence of S9-mix, the 
frequency of binucleated cells with micronuclei was comparable to that of negative controls (values of 
p ≤ 0.05 were considered as significant). It was concluded that 3-methyl-2-cyclopenten-1-one did not 
induce micronuclei in cultured human peripheral blood lymphocytes when tested up to 10 mM under 
the experimental conditions employed (Watters, 2014). 
Conclusion on genotoxicity from FGE.212Rev3 
The genotoxicity of the flavouring substance 3-methyl-2-cyclopenten-1-one [FL-no: 07.112] was 
assessed by means of two in vitro assays (gene mutations in bacteria and micronuclei in human 
lymphocytes). 3-Methyl-2-cyclopenten-1-one did not induce gene mutations in bacteria with or 
without metabolic activation when tested under the conditions employed in the study as presented by 
the applicant. Neither did it induce micronuclei in cultured human blood lymphocytes under the test 
conditions employed with or without metabolic activation for this study. Therefore, there is no concern 
with respect to genotoxicity and the substance 3-methyl-2-cyclopenten-1-one [FL-no: 07.112] can be 
evaluated through the Procedure. This conclusion is also valid for three other five-carbon ring 
substances [FL-no: 07.033, 07.094, 07.140 and 07.219]. 
Summaries of the in vitro and in vivo genotoxicity data from FGE.212Rev1 and FGE.212Rev3 are given 
in Tables 7, 8 and 9. 
2.4.5. EFSA considerations on genotoxicity 
Data not available for the JECFA at the time of evaluation (59th meeting) for cyclohexanone [FL-no: 
07.148] have been considered by EFSA. Results from in vitro genotoxicity studies with cyclohexanone, 
carried out by NTP, have been published on the NTP website (NTP, 2007). From the technical 
information also provided there, it can be concluded that the tests by NTP are reliable. A set of Ames 
tests with Salmonella strains TA98, TA100, TA1535 and TA1537) and a study with mouse lymphoma 
cells (L5178Y; tk+/-), including cloning efficiency and colony sizing provided convincingly negative 
results. The tests were carried out with and without metabolic activation at cyclohexanone levels up to 
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10000 µg/plate in the Ames tests and up to 5000 µg/mL in the mouse lymphoma assay. For a 
summary of these studies see Table 10. 
The Panel noted that cyclohexanone has also been studied in long term carcinogenicity studies in mice 
(up to 6.2 g/kg bw per day) and rats (up to 0.65 g/kg bw per day) (Lijinsky and Kovatch, 1986). The 
substance was tested up to the maximum tolerated dose levels and the overall conclusion from these 
studies was that cyclohexanone is not carcinogenic. In an evaluation of these studies the IARC 
concluded that the substance was not classifiable as to its carcinogenicity to humans (IARC, 1989). 
For eleven candidate substances [FL-no: 07.033, 07.034, 07.035, 07.094, 07.098, 07.112, 07.126, 
07.129, 07.140, 07.172 and 09.930] it has been concluded in FGE.211, FGE.212Rev1 and 
FGE.212Rev3, respectively, that a concern for genotoxicity, indicated by the presence of a structural 
alert, could be ruled out based on experimental data for representative substances. For [FL-no: 
07.033], the Panel notes that this evaluation is only applicable to the structures that have been 
presented for this substance in FGE.212Rev3. However, since it is not clear if these structures actually 
reflect the chemical substance used as ‘isojasmone’ the Panel decided that further consideration of 
[FL-no: 07.033] is not possible.  
Therefore, the Panel concluded that the data available do not preclude evaluation of 23 JECFA 
evaluated alicyclic ketones, secondary alcohols and related esters through the Procedure. 
3. Assessment 
3.1. Application of the Procedure to 24 alicyclic ketones, secondary 
alcohols or related esters evaluated by the JECFA (JECFA, 2003) 
According to the JECFA six of the substances belong to structural class I and 18 to structural class II 
using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded all 24 alicyclic ketones, secondary alcohols or related esters at step A3 in the 
JECFA Procedure – i.e. the substances are expected to be metabolised to innocuous products (step 2) 
and the intakes for all substances are below the thresholds for structural classes I and II (step A3).  
In conclusion, the JECFA evaluated all 24 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
The evaluations of the 24 substances are summarised in Table 11 (JECFA, 2003). 
3.2. Application of the Procedure to 22 secondary alicyclic saturated and 
unsaturated alcohols, ketones and esters containing secondary 
alicyclic alcohols by EFSA in FGE.09Rev6 (EFSA CEF Panel, 2015b) 
Twenty-two flavouring substances were evaluated in FGE.09Rev6. Fourteen substances are classified 
into structural class I, seven into structural class II and one into structural class III using the decision 
tree approach presented by Cramer et al. (Cramer et al., 1978). 
Twenty-one substances were concluded at step A3 using the EFSA Procedure – i.e. the substances are 
expected to be metabolised to innocuous products (step 2) and the estimated daily intakes  are below 
the thresholds of concern for their structural classes (step A3). 
For one substance methyl 3-oxo-2-pentyl-1-cyclopentylacetate [FL-no: 09.520] the estimated daily 
intake exceeds the threshold of concern for structural class II and since the substance is not 
endogenous the substance proceeds to step A5. 
A 90 day study in rats has been performed for [FL-no: 09.520] from which a No Observed Adverse 
Effect Level (NOAEL) of 100 mg/kg bw per day could be derived. This NOAEL provides a margin of 
safety of nearly 104 compared to the daily intake of 0.013 mg/kg bw per day for methyl 3-oxo-2-
pentyl-1-cyclopentylacetate. Therefore, [FL-no: 09.520] does not pose a safety concern when used at 
estimated levels of intake, based on the MSDI approach, as a flavouring substance. 
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In conclusion, the Panel considered that 22 of the substances evaluated through the Procedure were 
of no safety concern at the estimated levels of intakes based on the MSDI approach. For one 
substance additional data were required. 
The stepwise evaluations of the 22 substances are summarised in Table 12 (EFSA CEF Panel, 2015b). 
3.3. EFSA considerations 
Since for one ([FL-no: 07.033]) of the 24 candidate substances evaluated by JECFA (2003) the 
chemical identity is not clear ([FL-no: 07.033]), the Panel could only consider the evaluation of 23 
JECFA-evaluated substances. The Panel agrees with the application of the Procedure as performed by 
the JECFA for these 23 substances in the group of alicyclic ketones, secondary alcohols and related 
esters. 
4. Conclusions 
The present revision of FGE.51, FGE.51Rev2, is due to new genotoxicity data evaluated in 
FGE.212Rev3. Based on these data, the Panel concluded that the data available could rule out the 
concern for genotoxicity for [FL-no: 07.033, 07.094, 07.112 and 07.140] and accordingly these four 
substances can be evaluated through the Procedure in this revision of FGE.51. Three of these 
substances were evaluated by the JECFA at its 59th meeting in 2002 [FL-no: 07.033, 07.094 and 
07.112] and the fourth was evaluated by the JECFA at its 63rd meeting. These two JECFA evaluations 
comprise together 57 flavouring substances, five of which are not in the Register and two are no 
longer supported by industry for use as flavouring substances in Europe. Of the remaining 50 
substances, 26 substances have been evaluated in other FGEs or opinions, leaving 24 flavouring 
substances to be considered in the current revision of FGE.51. 
The Panel concluded that the 24 substances in the JECFA flavouring groups of alicyclic ketones, 
secondary alcohols and related esters and monocyclic and bicyclic secondary alcohols, ketones and 
related esters are structurally related to the group of secondary alicyclic saturated and unsaturated 
alcohols, ketones and esters with secondary alicyclic alcohol moieties evaluated by EFSA in Flavouring 
Group Evaluation 09, Revision 6 (FGE.09Rev6) (EFSA CEF Panel, 2015b). 
For one of these 24 substances ([FL-no: 07.033]) the chemical identity could not be unambiguously 
confirmed. Therefore the Panel could not consider the JECFA evaluation of this substance. Therefore, 
the current revision of FGE.51 will deal with 23 JECFA-evaluated substances. 
For all 23 substances considered in this FGE, the Panel concluded that either they did not raise a 
concern with respect to genotoxicity, or that concerns with respect to genotoxicity due to the 
presence of a structural alert for this could be ruled out, based on experimental data. 
The Panel agrees with the application of the Procedure as performed by the JECFA for the 23 
substances considered in this FGE. 
For 23 JECFA evaluated alicyclic ketones, secondary alcohols and related esters [FL-no: 02.209, 
07.034, 07.035, 07.045, 07.094, 07.095, 07.098, 07.112, 07.126, 07.129, 07.140, 07.148, 07.149, 
07.172, 07.179, 07.180, 07.257, 09.027, 09.140, 09.160, 09.230, 09.464 and 09.930] the Panel 
agrees with the JECFA conclusion ‘no safety concern at estimated levels of intake as flavouring 
substance’ based on the MSDI approach. 
In order to determine whether the conclusion for the JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications: Adequate 
specifications including complete purity criteria and identity tests are available for 21 JECFA-evaluated 
substances. For [FL-no: 07.094 and 07.112] information on the solubility in water and ethanol is 
missing and therefore the conclusions on the named substance cannot be applied to the materials of 
commerce that correspond to these two FL-numbers. For substance [FL-no: 07.033] unambiguous 
information with respect to the chemical identity should be provided. 
For all substances use levels are needed to calculate the mTAMDIs in order to identify those 
flavouring substances that need more refined exposure assessment and to finalise the evaluation. 
  
Flavouring Group Evaluation 51, Revision 2 
 
 
 
www.efsa.europa.eu/efsajournal 25  EFSA Journal 2016;14(1):4338 
 
Documentation provided to EFSA  
1. Barsky FC, 1976. In vitro microbial mutagenicity studies of cyclohexanol, with cover letter dated 
10/3/1995. Cyclohexanol. E. I. Dupont De Nemour & Co. Lab. no. 9822, study no. 755-75. EPA 
Doc 86960000143S, microfiche no. OTS0558283. January 7, 1977. Unpublished report 
submitted by EFFA to FLAVIS Secretariat. 
2. Beevers C, 2010. Reverse mutation in five histidine-requiring strains of Salmonella typhimurium. 
1(7),8-p-menthadien-2-yl acetate. Covance Laboratories Ltd, England. Study no. 8213039. April 
2010. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
3. Bowen R, 2014. 3-methyl-2-cyclopenten-1-one: Bacterial reverse mutation assay. Covance 
Laboratories Ltd. Study no. 8302484. 23 October 2014. Unpublished report submitted by EFFA 
to DG SANTE. 
4. Cifone MA, 2001. ST 08 C 99: L5178Y TK +/- mouse lymphoma forward mutation assay with a 
confirmatory assay. Methyl 3-oxo-2-pentyl-1-cyclopentylacetate. Covance Laboratories Inc., 
Vienna, Virginia. Study no. 21997-0-431 ICH. February 27, 2001. Unpublished report submitted 
by EFFA to FLAVIS Secretariat. 
5. Durward R, 2001. ST 41 C 00: In vivo Liver Unscheduled DNA Synthesis (UDS) assay. Methyl 3-
oxo-2-pentyl-1-cyclopentylacetate. Safepharm Laboratories Limited, Derby, U.K. Project no. 
161/266. 08 August 2001. Unpublished report submitted by EFFA to the FLAVIS Secretariat. 
6. EFFA (European Flavour Association), 2010. EFFA Letters to EFSA for clarification of 
specifications and isomerism for which data were requested in published FGEs. 
7. EFFA (European Flavour Association), 2012. Private Communication forwarded to FLAVIS 
Secretariat, Danish Food Institute, Technical University of Denmark. Dated 17 January 2012, 
14, 23 and 24 February 2012 and 19 March 2012. Specification data related to substances in 
FGE.29.Rev1: [FL-no: 01.015]; FGE.09Rev4 [FL-no: 07.059, 09.843 and 09.920] and 
FGE.51Rev1 [FL-no: 07.034, 07.035, 07.095, 07.129, 07.172, 07.257 and 09.930]. 
FLAVIS/8.143. 
8. Food and Drug Research Laboratories, Inc., 1975. Mutagenic evaluation of compound FDA 71-
57, menthol. Litton Bionetics, Inc. Weir, R.J. January 14, 1975. Unpublished report submitted 
by EFFA to FLAVIS Secretariat. 
9. Gelbke H-P, 1991. Cytogenetic study in vivo of cyclohexanol in mice: Micronucleus test: Single 
oral administration of cyclohexanol, with cover letter dated 9/11/95. BASF Abteilung 
Toxikologie. Engelhardt, G. Project no. 26H0843/894490. EPA Doc 86950000355, microfiche no. 
OTS0557795. September 11, 1995. Unpublished report submitted by EFFA to SCF. 
10. Gudi R and Krsmanovic L, 1998. Mammalian erythrocyte micronucleus test. Methyl 3-oxo-2-
pentyl-1-cyclopentylacetate. MA BioServices, Inc, Rockville, MD. Lab no. G98AN94.123. August 
4, 1998. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
11. Morishita K, Schoonhoven R and Swenberg JA, 1997. Mechanistic studies on isophorone and 
preputial gland carcinomas. Department of Environmental Sciences and Engineering, University 
of North Carolina, Chapel Hill, N.C. March 25, 1997. Unpublished report submitted by EFFA to 
FLAVIS secretariat. 
12. Ross C and Harris WJ, 1979. Testing of compound 0478/5 in the mouse lymphoma specific 
locus mutation assay. Methyl 3-oxo-2-pentyl-1-cyclopentylacetate. Inveresk Research 
International, Edinburgh, Scotland. Project no. 410917. October 1979. Unpublished report 
submitted by EFFA to FLAVIS Secretariat. 
Flavouring Group Evaluation 51, Revision 2 
 
 
 
www.efsa.europa.eu/efsajournal 26  EFSA Journal 2016;14(1):4338 
 
13. Thompson PW, 2000. ST 41 C 00: Reverse mutation assay ‘Ames test’ using Salmonella 
typhimurium. Methyl 3-oxo-2-pentyl-1-cyclopentylacetate. Safepharm Laboratories Limited, 
Derby, U.K. Project no. 161/265. 11 October 2000. Unpublished report submitted by EFFA to 
FLAVIS Secretariat. 
14. Wagner VO and Klug ML, 2000. ST 08 C 99: Bacterial reverse mutation assay. Methyl 3-oxo-2-
pentyl-1-cyclopentylacetate. BioReliance, Rockville, MD. Study no. AA31NK.502.BTL. August 28, 
2000. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
15. Watters B, 2014. 3-methyl-2-cyclopenten-1-one: In Vitro Human Lymphocyte Micronucleus 
Assay. Covance Laboratories Ltd. Study no. 8302485. 3 October 2014. Unpublished report 
submitted by EFFA to DG SANTE. 
16. Whitwell J, 2010. Induction of micronuclei in cultured human peripheral blood lymphocytes. 
1(7),8-p-menthadien-2-yl acetate. Covance Laboratories Ltd, England. Study no. 822021. April 
2010. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
References 
Aaron CS, Brewen JG, Stetka DG, Bleicher WT and Spahn MC, 1985. Comparative mutagenesis in 
mammalian cells (CHO) in culture: multiple genetic endpoint analysis of cyclohexanone in vitro. 
Environmental Mutagenesis 7 (Suppl. 3), 60–61. 
Andersen PH and Jensen NJ, 1984. Mutagenic investigation of peppermint oil in the 
Salmonella/mammalian-microsome test. Mutation Research 138, 17–20. 
Brusick DJ, 1986. Genotoxic effects in cultured mammalian cells produced by low pH treatment 
conditions and increased ion concentrations. Environmental Mutagenesis 8, 879–886. 
Collin J-P, 1971. Effet cytogénétique du cyclamate de soude, da la cyclohéxanone et du cyclohéxanol. 
[Cytogenetic effect of cyclamate, cyclohexanone and cyclohexanol]. Le Diabete 19, 215–221. (In 
French) 
Cramer GM, Ford RA and Hall RL, 1978. Estimation of toxic hazard - a decision tree approach. Food 
and Cosmetics Toxicology 16(3), 255–276. 
Dyshlovoi VD, Boiko NL, Shemetun AM and Kharchenko TI, 1981. [Cytogenetic action of 
cyclohexanone]. Gigiena i sanitaria 5, 76–77. (In Russian) 
EFSA (European Food Safety Authority), 2008a. Scientific Opinion of the Scientific Panel on Food 
Additives, Flavourings, Processing Aids and Materials in contact with food related to Flavouring 
Group Evaluation 51 (FGE.51): Consideration of alicyclic ketones and secondary alcohols and 
related esters evaluated by JECFA (59th meeting) and structurally related to alicyclic ketones, 
secondary alcohols and related esters evaluated by EFSA in FGE.09 (2004) (Commission Regulation 
(EC) No 1565/2000 of 18 July 2000). The EFSA Journal (2008) 855, 1–32. 
EFSA (European Food Safety Authority), 2008b. Scientific opinion of the Panel on Food Additives, 
Flavourings, Processing Aids and Materials in contact with Food (AFC) on a request from the 
Commission on Camphor in flavourings and other food ingredients with flavouring properties. The 
EFSA Journal (2008) 729, 1–15. 
EFSA (European Food Safety Authority), 2008c. Genotoxicity Test Strategy for Substances belonging 
to Subgroups of FGE.19 - Statement of the Panel on Food Contact Materials, Enzymes, Flavourings 
and Processing Aids (CEF). The EFSA Journal (2008) 854, 1–5. 
EFSA (European Food Safety Authority), 2009. Scientific Opinion of the Scientific Panel on Food 
Additives, Flavourings, Processing Aids and Materials in contact with food related to Flavouring 
Group Evaluation 212 (FGE.212):  α, β−Unsaturated alicyclic ketones and precursors from chemical 
subgroup 2.6 of FGE.19 (Commission Regulation (EC) No 1565/2000 of 18 July 2000). The EFSA 
Journal (2009) 878, 1–28. 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2011a. Scientific Opinion on Flavouring Group Evaluation 211 (FGE.211): Consideration of 
Flavouring Group Evaluation 51, Revision 2 
 
 
 
www.efsa.europa.eu/efsajournal 27  EFSA Journal 2016;14(1):4338 
 
genotoxicity data on representatives for one  α, β−unsaturated ketone and three precursors from 
chemical subgroup 2.5 of FGE.19 by EFSA. EFSA Journal 2011;9(3):1993, 13 pp. 
doi:10.2903/j.efsa.2011.1993 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2011b. Scientific Opinion on Flavouring Group Evaluation 212 Revision 1 (FGE.212Rev1): 
 α, β−Unsaturated alicyclic ketones and precursors from chemical subgroup 2.6 of FGE.19. EFSA 
Journal 2011;9(3):1923, 29 pp. doi:10.2903/j.efsa.2011.1923 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2011c. Scientific Opinion on Flavouring Group Evaluation 96 (FGE.96): Consideration of 88 
flavouring substances considered by EFSA for which EU production volumes / anticipated 
production volumes have been submitted on request by DG SANCO. Addendum to FGE. 51, 52, 53, 
54, 56, 58, 61, 62, 63, 64, 68, 69, 70, 71, 73, 76, 77, 79, 80, 83, 84, 85 and 87. EFSA Journal 
2011;9(12):1924, 60 pp. doi:10.2903/j.efsa.2011.1924 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2011d. Scientific Opinion on Flavouring Group Evaluation 9, Revision 3 (FGE.09Rev3): Secondary 
alicyclic saturated and unsaturated alcohols, ketones and esters containing secondary alicyclic 
alcohols from chemical group 8 and 30, and an ester of a phenol derivative from chemical group 
25. EFSA Journal 2011;9(10):2396, 68 pp. doi:10.2903/j.efsa.2011.2396 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2012. Scientific Opinion on Flavouring Group Evaluation 51, Revision1 (FGE.51Rev1): Consideration 
of alicyclic ketones and secondary alcohols and related esters evaluated by the JECFA (59th 
meeting) structurally related to alicyclic ketones secondary alcohols and related esters in 
FGE.09Rev3 (2011). EFSA Journal 2012;10(4):2636, 52 pp. doi:10.2903/j.efsa.2012.2636 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2015a. Scientific Opinion on Flavouring Group Evaluation 212, Revision 3 (FGE.212Rev3): 
α, β−Unsaturated alicyclic ketones and precursors from chemical subgroup 2.6 of FGE.19. EFSA 
Journal 2015;13(5):4116, 39 pp. doi:10.2903/j.efsa.2015.4116 
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2015b. Scientific Opinion on Flavouring Group Evaluation 09 Revision 6 (FGE.09Rev6): Secondary 
alicyclic saturated and unsaturated alcohols, ketones and esters containing secondary alicyclic 
alcohols from chemical group 8 and 30, and an ester of a phenol derivative from chemical group 
25. EFSA Journal 2015;13(9):4243, 81 pp. doi:10.4243/j.efsa.2015.4243 
EPA (United States Environmental Protection Agency), 1997. Mechanistic studies on isophorone and 
preputial gland carcinomas (Morishita K, Schoonhoven R and Swenberg J), with cover letter dated 
4/15/1997. EPA/OTS; Doc #86970000764. (This reference covers Morishita et al., 1997). 
Florin I, Rutberg L, Curvall M and Enzell CR, 1980. Screening of tobacco smoke constituents for 
mutagenicity using the Ames' test. Toxicology 18, 219–232a. 
Foureman P, Mason JM, Valencia R and Zimmering S, 1994. Chemical mutagenesis testing in 
Drosophila. X. Results of 70 coded chemicals tested for the National Toxicology Program. 
Environmental and Molecular Mutagenesis 23, 208–227. 
Franzios G, Mirotsou M, Hatziapostolou E, Kral J, Scouras ZG and Mavragani-Tsipidou P, 1997. 
Insecticidal and genotoxic activities of mint essential oils. Journal of Agricultural and Food 
Chemistry 45(7), 2690–2694. 
Gomes-Carneiro MR, Felzenszwalb I and Paumgartten FJ, 1998. Mutagenicity testing (+/-)-camphor, 
1,8-cineole, citral, citronellal, (-)-menthol and terpineol with the Salmonella/microsome assay. 
Mutation Research 416, 129–136. 
Goncharova RI, 1970. [Genetic activity of some cyclohexane derivatives]. Tsitologia i genetika 137-
142. (In Russian) 
Gulati DK, Witt K, Anderson B, Zeiger E and Shelby M, 1989. Chromosome aberration and sister-
chromatid exchange test in Chinese hamster ovary cells in vitro III: Results with 27 chemicals. 
Environmental and Molecular Mutagenesis 13, 133–193. 
Flavouring Group Evaluation 51, Revision 2 
 
 
 
www.efsa.europa.eu/efsajournal 28  EFSA Journal 2016;14(1):4338 
 
Haworth S, Lawlor T, Mortelmans K, Speck W and Zeiger E, 1983. Salmonella mutagenicity test results 
for 250 chemicals. Environmental Mutagenesis 5(Suppl. 1), 3–142. 
Honma M, Hayashi M, Shimada H, Tanaka N, Wakuri S, Awogi T, Yamamoto KI, Kodani N-U, Nishi Y, 
Nakadate M and Sofuni T, 1999a. Evaluation of the mouse lymphoma tk assay (microwell method) 
as an alternative to the in vitro chromosomal aberration test. Mutagenesis 14(1), 5–22. 
Honma M, Zhang L-S, Sakamoto H, Ozaki M, Takeshita K, Momose M, Hayashi M and Sufuni T, 1999b. 
The need for long-term treatment in the mouse lymphoma assay. Mutagenesis 14(1), 23–29. 
IARC (International Agency for Research on Cancer), 1989. IARC Monographs on the evaluating of 
carcinogenic risks to humans. IARC Working Group meeting on the evaluation of carcinogenic risks 
to humans. Lyon, 18-25 October 1988. Cyclohexanone. IARC Monographs 47, Lyon, pp. 157–169. 
Ishidate Jr M, Sofuni T, Yoshikawa K, Hayashi M, Nohmi T, Sawada M and Matsuoka A, 1984. Primary 
mutagenicity screening of food additives currently used in Japan. Food and Chemical Toxicology 
22(8), 623–636. 
Ivett JL, Brown BM, Rodgers C, Anderson BE, Resmick MA and Zeiger E, 1989. Chromosomal 
aberrations and sister chromatid exchange tests in Chinese hamster ovary cells in vitro. IV. Results 
with 15 chemicals. Environmental and Molecular Mutagenesis 14, 165–187. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1995. Evaluation of certain food 
additives and contaminants. Forty-fourth Meeting of the Joint FAO/WHO Expert Committee on 
Food Additives. 14-23 February 1995. WHO Technical Report Series, no. 859. Geneva  
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1996. Toxicological evaluation of 
certain food additives. Forty-fourth Meeting of the Joint FAO/WHO Expert Committee on Food 
Additives and contaminants. WHO Food Additives Series: 35. IPCS, WHO, Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1997. Evaluation of certain food 
additives and contaminants. Forty-sixth report of the Joint FAO/WHO Expert Committee on Food 
Additives. Geneva, 6-15 February 1996. WHO Technical Report Series, no. 868. Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1999. Evaluation of certain food 
additives and contaminants. Forty-ninth report of the Joint FAO/WHO Expert Committee on Food 
Additives. Rome, 17-26 June 1997. WHO Technical Report Series, no. 884. Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2002. Compendium of food additive 
specifications. Addendum 10. Joint FAO/WHO Expert Committee of Food Additives 59th session. 
Geneva, 4-13 June 2002. FAO Food and Nutrition paper 52 Addition 10. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2003. Safety evaluation of certain food 
additives. Fifty-ninth Meeting of the Joint FAO/WHO Expert Committee on Food Additives, WHO 
Food Additives Series: 50. IPCS, WHO, Geneva. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2005. Evaluation of certain food 
additives. Sixty-third report of the Joint FAO/WHO Expert Committee on Food Additives. WHO 
Technical Report Series, no. 928. Geneva, 8–17 June 2004. 
JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2006. Sixty-seventh Meeting. Rome, 
20-29 June 2006, Summary and Conclusions. Issued 7 July 2006. 
Lederer J, Collin JP, Pottier-Arnould AM and Gondry E, 1971. [Cytogenetic and teratogenetic effect of 
cyclamate and its metabolites]. Therapeutique 47, 357–363. (In French) 
Lijinsky W and Kovatch RM, 1986. Chronic toxicity study of cyclohehanone in rats and mice. Journal of 
the National Cancer Institute 77(4), 941–949. 
Massoud A, Aly A and Shafik H, 1980. Mutagenicity and carcinogenicity of cyclohexanone. Mutation 
Research 74(3), 174. 
Matsui S, Yamamoto R and Yamada H, 1989. The Bacillus Subtilis/Microsome rec-assay for the 
detection of DNA damaging substances which may occur in chlorinated and ozonated waters. 
Water Science & Technology 21, 875–887. 
Flavouring Group Evaluation 51, Revision 2 
 
 
 
www.efsa.europa.eu/efsajournal 29  EFSA Journal 2016;14(1):4338 
 
Matsuoka A, Yamakage K, Kusakabe H, Wakuri S, Asakura M, Noguchi T, Sugiyama T, Shimada H, 
Nakayama S, Kasahara Y, Takahashi Y, Miura KF, Hatanaka M, Ishidate M, Morita T, Watanabe K, 
Hara M, Odawara K, Tanaka N, Hayashi M and Sofuni T, 1996. Re-evaluation of chromosomal 
aberration induction on nine mouse lymphoma assay 'unique positive' NTP carcinogens. Mutation 
Research 369, 243–252. 
McGregor DB, Brown A, Cattanach P, Edwards I, McBride D, Riach C and Caspary WJ, 1988. 
Responses of the L5178Y tk+/tk- mouse lymphoma cell forward mutation assay: III. 72 coded 
chemicals. Environmental and Molecular Mutagenesis 12, 85–153. 
McKee RH, Phillips RD, Lerman SA, Slesinski RS, Rogers-Back AM, Curren RD and Putman DL, 1987. 
The genotoxic potential of isophorone. Environmental Mutagenesis 9(8), 71. 
McMahon RE, Cline JC and Thompson CZ, 1979. Assay of 855 test chemicals in ten tester strains using 
a new modification of the Ames test for bacterial mutagens. Cancer Research 39, 682–693. 
Moreland DE, 1994. Oxidative phosphorylation and photophosphorylation. In: Hodgson E and Levi P 
(Eds.). Introduction to Biochemical Toxicology, 2nd Ed. Appleton and Lange, Norwalk, pp. 364–
366. 
Morimoto T, 2005. Bacterial reverse mutation study of menthyl 3-hydroxybutyrate. Study No. 235. 
February 21, 2005. Private communication to the Flavor and Extract Manufacturers Association, 
Washington, DC, USA. Submitted to WHO by the International Organization of the Flavour 
Industry, Brussels, Belgium. 
Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B and Zeiger E, 1986. Salmonella mutagenicity 
tests II. Results from the testing of 270 chemicals. Environmental and Molecular Mutagenesis 
8(Suppl. 7), 1–119. 
Murthy PBK, Ahmed MM and Regu K, 1991. Lack of genotoxicity of menthol in chromosome aberration 
and sister chromatid exchange assays using human lymphocytes in vitro. Toxicology In Vitro 5(4), 
337–340. 
Myhr BC and Caspary WJ, 1991. Chemical mutagenesis at the thymidine kinase locus in L5178Y 
mouse lymphoma cells: Results for 31 coded compounds in the national toxicology program. 
Environmental and Molecular Mutagenesis 18, 51–83. 
Nohmi T, Miyata R, Yoshikawa K and Ishidate M, 1985. [Mutagenicity tests on organic chemical 
contaminants in city water and related compounds. I. Bacterial mutagenicity tests]. Eisei Shikenjo 
hokoku. Bulletin of National Institute of Hygienic Sciences 103(60), 60–64. (In Japanese) 
NTP (National Toxicology Program), 1986. Toxicology and carcinogenesis studies of isophorone (CAS 
no. 78-59-1) in F344/N rats and B6C3F1 mice (gavage studies). NTP-TR 291. NIH Publication no. 
86–2547. 
NTP (National Toxicology Program), 1990a. Toxicology and carcinogenesis studies of d-carvone (CAS. 
no. 2244-16-8) in B6C3F1 mice (gavage studies). February 1990. NTP-TR 381. NIH Publication no. 
90-2836. 
NTP (National Toxicology Program), 1990b. In vivo mouse bone marrow chromosomal aberrations 
Test. Data. http://tools.niehs.nih.gov/cebs3/ntpViews/?studyNumber=783723&subStudyType=CA 
NTP (National Toxicology Program), 2007. Search Result on cyclohexanone. http://ntp-
apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=cyclohexa
none. [14th September, 2007]. 
O’Donoghue JL, Haworth SR, Curren RD, Kirby PE, Lawlor T, Moran EJ, Phillips RD, Putnam DL, 
Rogers-Back AM, Slesinski RS and Thilagar A, 1988. Mutagenicity studies on ketone solvents: 
Methyl ethyl ketone, methyl isobutyl ketone, and isophorone. Mutation Research 206, 149–161. 
Oda Y, Hamono Y, Inoue K, Yamamoto H, Niihara T and Kunita N, 1979. [Mutagenicity of food flavors 
in bacteria]. Osaka Furitsu Koshu Eisei Kenkyusho kenkyu hokoku. Shokuhin eisei hen 9, 177–181. 
(In Japanese) 
OECD (Organisation for Economic Co-operation and Development), 1997. Test No. 471. Bacteria 
Reverse Mutation Test. OECD Guideline for testing of chemicals, Section 4. Available online: 
Flavouring Group Evaluation 51, Revision 2 
 
 
 
www.efsa.europa.eu/efsajournal 30  EFSA Journal 2016;14(1):4338 
 
http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_
9789264071247-en. 
OECD (Organisation for Economic Co-operation and Development), 1997. Test No. 486. Unscheduled 
DNA Synthesis (UDS) Test with Mammalian Liver Cells In Vivo. OECD Guideline for testing of 
chemicals. Section 4. Available online: http://www.oecd-ilibrary.org/environment/test-no-486-
unscheduled-dna-synthesis-uds-test-with-mammalian-liver-cells-in-vivo_9789264071520-en. 
OECD (Organisation for Economic Co-operation and Development), 2010. Test No. 487: In Vitro 
Mammalian Cell Micronucleus Test. OECD Guidelines for the Testing of Chemicals, Section 4. 
Available online: http://www.oecd-ilibrary.org/environment/test-no-487-in-vitro-mammalian-cell-
micronucleus-test_9789264091016-en. 
OECD (Organisation for Economic Co-operation and Development), 2014. Test No. 474. Mammalian 
Erythrocyte Micronucleus Test. OECD Guideline for testing of chemicals. Section 4. Available online: 
http://www.oecd.org/env/test-no-474-mammalian-erythrocyte-micronucleus-test-9789264224292-
en.htm. 
SCF (Scientific Committee for Food), 1999. Opinion on a programme for the evaluation of flavouring 
substances (expressed on 2 December 1999). Scientific Committee on Food. 
SCF/CS/FLAV/TASK/11 Final 6/12/1999. Annex I to the minutes of the 119th Plenary meeting. 
European Commission, Health & Consumer Protection Directorate-General. 
Shelby MD and Witt KL, 1995. Comparison of results from mouse bone marrow chromosome 
aberration and micronucleus test. Environmental and Molecular Mutagenesis 25, 302–313. 
Shelby MD, Erexson GL, Hook GJ and Tice RR, 1993. Evaluation of a three-exposure mouse bone 
marrow micronucleus protocol: Results with 49 chemicals. Environmental and Molecular 
Mutagenesis 21(2), 160–179. 
Slater EC, 1963. Uncouplers and inhibitors of oxidative phosphorylation. In: Hochester RM and Quaste 
JJ (Eds.). Metabolic inhibitors. Vol. 2. Academic Press, New York, pp. 503–516. 
Slater EC, 1967. Application of inhibitors and uncouplers for a study of oxidative phosphorylation. In: 
Estabrook RW and Pullman ME (Eds.). Methods in Enzymology. Vol. 10. Academic Press, New York, 
pp. 48–57. 
Storer RD, McKelvey TW, Kraynak AR, Elia MC, Barnum JE, Harmon LS, Nichols WW and DeLuca JG, 
1996. Revalidation of the in vitro alkaline elution/rat hepatocyte assay for DNA damage: improved 
criteria for assessment of cytotoxicity and genotoxicity and results for 81 compounds. Mutation 
Research 368(2), 59–101. 
Thier R, Peter H, Wiegland HJ and Bolt HM, 1990. Letter to the Editors. DNA binding study of 
isophorone in rats and mice. Archives of Toxicology 64, 684–685. 
Wild D, King MT, Gocke E and Eckhard K, 1983. Study of artificial flavouring substances for 
mutagenicity in the Salmonella/microsome, BASC and micronucleus tests. Food and Chemical 
Toxicology 21(6), 707–719. 
Yoo YS, 1986. Mutagenic and antimutagenic activities of flavoring agents used in foodstuffs. Osaka 
City Medical Journal 34(3–4), 267–288. 
Zeiger E, Anderson B, Haworth S, Lawlor T and Mortelmans K, 1988. Salmonella mutagenicity tests: 
IV. Results from the testing of 300 chemicals. Environmental and Molecular Mutagenesis 11(Suppl. 
12), 1–158. 
  
Flavouring Group Evaluation 51, Revision 2 
 
 
 
www.efsa.europa.eu/efsajournal 31  EFSA Journal 2016;14(1):4338 
 
Abbreviations 
bw body weight 
CAS Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO Chinese hamster ovary (cells) 
CoE Council of Europe 
DNA deoxyribonucleic acid 
EPA United States Environmental Protection Agency 
FAO Food and Agriculture Organization of the United Nations 
FEMA Flavor and Extract Manufacturers Association 
FGE Flavouring Group Evaluation 
FLAVIS (FL) Flavour Information System (database) 
GLP good laboratory practise 
ID identity 
IR infrared spectroscopy 
JECFA Joint FAO/WHO Expert Committee on Food Additives 
MS mass spectrometry  
MSDI maximised survey-derived daily intake 
mTAMDI modified theoretical added maximum daily intake 
NCE normochromatic erythrocyte 
NOEL no observed effect level 
NOAEL no observed adverse effect level 
NMR nuclear magnetic resonance 
NTP National Toxicology Program 
OECD Organization for Economic Co-operation and Development 
(Q)SAR (quantitative) structure-activity relationship 
SCE sister chromatic exchange 
SCF Scientific Committee on Food 
WHO World Health Organization 
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Appendix A – Summary of genotoxicity and toxicity data 
Table 3:  Summary of genotoxicity data for alicyclic ketones, secondary alcohols and related esters evaluated by the JECFA (JECFA, 2003) 
Chemical Name [FL-
no] 
[JECFA-no]  
Structural formula End-point Test system Maximum 
concentration 
Results Reference 
In vitro 
Cyclohexyl acetate 
09.027 
1093 
 
DNA damage B. subtilis H17(rec+), 
M45 (rec–) 
19 µg(d)/disc Negative(a) (Yoo, 1986) 
Cyclohexyl butyrate 
09.230 
1094 O
O
 
DNA damage B. subtilis H17(rec+), 
M45 (rec-) 
19 µg(d)/plate Negative(a) (Oda et al., 1979) 
2-
hexylidenecyclopentan-
1-one 
07.034 
1106 
O
 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537, TA1538 
5 concentrations, 
up to cytotoxicity  
or max 3600 
µg/plate. 
Negative(a) (Wild et al., 1983) 
2,2,6-
Trimethylcyclohexanon
e 
07.045 
1108 
O
 
Reverse mutation S. typhimurium TA98, 
TA100, 
TA1535,TA1537 
4.2–3600 
µg(d)/plate 
Negative(a) (Florin et al., 1980) 
3,5,5-
Trimethylcyclohex-2-
en-1-one 
07.126 
O
 
Foreward mutation test Mouse lymphoma 
L5178Y Tk+/- cells 
0 – 1600 µg/mL Positive(b) (McGregor et al., 
1988) 
O
O
Flavouring Group Evaluation 51, Revision 2 
 
 
www.efsa.europa.eu/efsajournal 33 EFSA Journal 2016;14(1):4338 
 
 
Chemical Name [FL-
no] 
[JECFA-no]  
Structural formula End-point Test system Maximum 
concentration 
Results Reference 
Cyclohexanone 
07.148 
1100 
O
 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
33–10000 
µg(d)/plate 
Negative(a) (Haworth et al., 
1983) 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
2.9–2900 
µg(d)/plate 
Negative(a) (Florin et al., 1980) 
Chromosomal  Chinese hamster 
ovary  cells aberration 
7.5 µl(d)/mL Negative(a) (Aaron et al., 1985) 
Chromosomal  Human lymphocytes 
aberration 
9.8–980 µg(d)/mL Positive(a) (Lederer et al., 
1971) 
Chromosomal  Human lymphocytes 
aberration 
0.005–0.1 µg(d)/mL Positive(a) (Dyshlovoi et al., 
1981) 
Sister chromatid exchange Chinese hamster 
ovary  cells 
7.5 µl/mL Negative(b) 
Positive(c) 
(Aaron et al., 1985) 
Cyclopentanone 
07.149 
1101 
O
 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
2.5–2500 
µg(d)/plate 
Negative(a) (Florin et al., 1980) 
In vivo       
2-
hexylidenecyclopentan-
1-one 
07.034 
1106 
 
O
 
Sex-linked recessive lethal 
mutation 
D. melanogaster 10 mM Negative (Wild et al., 1983) 
Micronucleus assay NMRI mice (4/group) 0, 166, 333, 500 
mg/kg bw; single 
dose, 30 h 
expression time 
Negative (Wild et al., 1983) 
Cyclohexanone 
07.148 
1100 
O
 
Sex-linked recessive lethal 
mutation 
D. melanogaster 0.1 mL/100 mL Negative (Goncharova, 1970) 
(a): With and without metabolic activation. 
(b): Without metabolic activation. 
(c): With metabolic activation. 
(d): In the original JECFA report the figures for Maximum concentration were written as ‘mg’. This is a mistake by the JECFA as the concentration in the original references is reported in ‘µg’. 
Therefore ‘mg’ has been replaced by ‘µg’.   
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Table 4:  Genotoxicity data (in vitro) evaluated by EFSA in FGE.09Rev3 (substances in brackets are JECFA-evaluated substances) 
Chemical Name 
[FL-no]  
Test System Test Object  Concentration Result  Reference  Comments  
(Menthol [02.015]) Ames test S. typhimurium TA92, 
TA94, TA98, TA100, 
TA1535, TA1537 
0, and 6 
concentrations up 
to 5000 µg/plate 
Negative(a) (Ishidate et 
al., 1984) 
d, l-Menthol was used.  
The study is considered valid 
Ames test 
(preincubation 
method) 
S. typhimurium TA97, 
TA98, TA100, TA1535 
3–666 µg/plate  Negative(a) (Zeiger et al., 
1988) 
d, l-Menthol was used. The study is 
considered valid.  
Ames test S. typhimurium TA98, 
TA100, TA2637 
0, 5–500 µg/plate  Negative(a)  (Nohmi et al., 
1985) 
d, l-Menthol was tested. The highest 
concentrations were cytotoxic. The study is 
considered valid. 
Ames test S. typhimurium TA98, 
TA100, TA2637 
0, 20–500 
µg/plate  
Negative(a)  (Nohmi et al., 
1985) 
l-Menthol was tested. The highest 
concentrations were cytotoxic. The study is 
considered valid. 
Ames test S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
0, 6.4, 32, 160, 
and 800 µg/plate  
Negative(a)  (Andersen and 
Jensen, 1984) 
No indication of which enantiomer was used. 
In the absence of metabolic activation, the 
highest concentration was cytotoxic. The 
study is considered valid. 
Ames test E. coli WP2 uvrA (Trp-) 100–800 µg/plate  Negative  (Yoo, 1986) l-Menthol was used. The article is not in 
English. The validity of the study cannot be 
evaluated. It is unclear whether metabolic 
activation or a control group was used. 
Ames test  S. typhimurium TA97A, 
TA98, TA100, TA102 
0, 5–800 µg/plate  Negative(a)  (Gomes-
Carneiro et 
al., 1998) 
(-)-Menthol was used. The range of 
concentrations tested varied between the 
different strains. Cytotoxicity was observed 
with the highest concentrations tested with 
TA97A and, in the presence of metabolic 
activation, the highest concentration tested 
with TA102. The study is considered valid. 
Rec assay  B. subtilis H17, M45 Up to 10 000 
µg/disk  
Positive (Yoo, 1986) l-Menthol was used. Inhibition zone for rec- 
and rec+ was 42 and 23 mm, respectively. 
The article is not in English. It is not clear 
from the study whether metabolic activation, 
or a control group was used. The validity of 
this study cannot be assessed. The method 
(rec-assay) has poor predictive value. 
Rec assay  B. subtilis H17, M45 20 µg/disk  Negative (Oda et al., 
1979) 
l-Menthol was used. The article is not in 
English. Only one concentration level is 
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Chemical Name 
[FL-no]  
Test System Test Object  Concentration Result  Reference  Comments  
mentioned at a table. No data on metabolic 
activation or control group. The validity of 
this study cannot be evaluated. The method 
(rec-assay) has poor predictive value. 
Alkaline elution assay Rat hepatocytes  0, 0.1–1.3 mM  
(203.2 µg/mL(d)) 
Negative (Storer et al., 
1996) 
The experiment employed d-Menthol. An 
increase in DNA breaks was only observed at 
concentrations associated with cytotoxicity. 
The authors concluded that this was a false-
positive result. The study is considered valid.                         
Sister chromatid 
exchange 
Chinese hamster ovary 
cells 
5–50 and 0, 2–25 
µg/mL(c) 
0, 16–167 
µg/mL(b) 
Negative(a) (Ivett et al., 
1989) 
d, l-Mentol was used. The compound was 
tested up to toxic or nearly toxic 
concentration levels. The study is considered 
valid. 
Sister chromatid 
exchange 
Human lymphocytes 0, 0.1, 1, 10 mM  
(1563 µg/mL(d)) 
Negative(a)  (Murthy et al., 
1991) 
The study is considered valid. 
Cytogenetic assay Human embryonic lung 
cells 
0, 0.1, 1, 10 
µg/mL  
Negative  (Food and 
Drug 
Research 
Laboratories, 
Inc., 1975) 
The report does not mention exogenous 
metabolic activation. The study is considered 
valid. 
Chromosome 
aberration 
Chinese hamster 
fibroblasts 
0 and three 
concentrations up 
to 200 µg/mL  
Negative(c)  (Ishidate et 
al., 1984) 
The maximum concentration (cytotoxic) was 
selected by a preliminary test. The study is 
considered valid. 
Chromosome 
aberration 
Chinese hamster ovary 
cells 
0, 50–250 µg/mL  Negative(a)  (Ivett et al., 
1989) 
d, l-Mentol was used. The compound was 
tested up to toxic or nearly toxic 
concentration levels. The study is considered 
valid. 
Chromosome 
aberration 
Human lymphocytes 0, 0.1, 1, 10 mM 
(1563 µg/mL(d))  
Negative(a)  (Murthy et al., 
1991) 
The study is considered valid. 
Gene mutation assay Mouse lymphoma 
L5178Y TK+/-cells 
0, 12.5–200 
µg/mL  
Negative(a)  (Myhr and 
Caspary, 
1991) 
d, l-Menthol was used. The maximum 
concentration was selected by a preliminary 
test The study is considered valid. 
(trans-Menthone 
[07.176]) 
Ames test  S. typhimurium TA97, 
TA98, TA100, TA1535, 
TA1537 
0, 6.4–800 
µg/plate  
Positive(a)  (Andersen and 
Jensen, 1984) 
Concentrations were selected based on 
preliminary experiments. In absence of 
metabolic activation, menthone was 
mutagenic only to strain TA1537 at 6.4 and 
32 µg/mL (slightly less than 2-fold increase in 
mutation frequency), but not at higher (toxic) 
concentrations. Also in absence of metabolic 
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Chemical Name 
[FL-no]  
Test System Test Object  Concentration Result  Reference  Comments  
activation, there was a concentration 
dependent increase in number of TA97 strain 
revertants (up to 4-fold increase at 600 µg/l). 
It was stated that metabolic activation did 
not enhance the mutagenicity of menthone. 
The study is considered valid. 
Cyclopentanol 
[02.135]  
Modified Ames test S. typhimurium G46, 
TA98, TA100, TA1535, 
C3076, TA1537, 
D3052, TA1538  
E. coli WP2, WP2 uvrA- 
0, 0.1–1000 
µg/mL  
Negative(a)  (McMahon et 
al., 1979) 
The study was performed with agar plates 
containing the following concentration 
gradients: 0.1 - 1, 1 - 10, 10 - 100, and 100 - 
1000 µg/mL. The study is considered valid, 
although tabulated data on cyclopentanol 
were not presented. 
(Cyclohexanone 
[07.148]) 
Ames test  S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
0, 33–10 000 
µg/plate  
Negative(a)  (Haworth et 
al., 1983) 
The highest level tested was the highest of 
either 10000 µg/plate, limit of solubility or 
maximal non-toxic concentration. The test 
was run twice. Both rat and hamster liver S9 
were used. The test is considered valid. 
 Ames test  S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
0, 3 µmol/plate  Negative(a)  (Florin et al., 
1980) 
A preliminary assay was performed with the 
four strains using only one concentration 
level (3 µmol/plate). This assay gave 
uncertain results. In addition, strains TA98 
and TA100 were exposed to 0.03 – 30 
µmol/plate. The validity of the study cannot 
be evaluated. 
 Ames test  S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
NR Positive (Massoud et 
al., 1980) 
Only an abstract is available. No reporting 
with respect to metabolic activation. The 
substance was also tested with Bacillus 
subtilis. With this specie, toxicity was found 
as well as a positive response. The validity of 
the study cannot be evaluated because of 
lack of experimental information. 
 Cytogenetic assay Human leukocytes 0.1–10 mM  Inconclusive(c)  (Collin, 1971) The study report contains little experimental 
detail. Gaps, but no increase in breaks, were 
observed without any dose response 
relationship. There was no information with 
respect to cytotoxicity or presence of a 
control group. Only a statement on 
observations from 12 cells per concentration 
was given, but the total number of cells 
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Chemical Name 
[FL-no]  
Test System Test Object  Concentration Result  Reference  Comments  
studied was not specified. The study is 
inadequate. 
Chromosomal 
aberration 
Human lymphocytes 0, 0.005–0.1 
µg/mL 
Positive  (Dyshlovoi et 
al., 1981) 
Article is not in English. Only an abstract 
available in English. The validity of the study 
cannot be evaluated.   
Gene mutation (HPRT) Chinese hamster ovary 
cells 
0, 7.5 µg/ml  Negative(a)  (Aaron et al., 
1985) 
Only an abstract is available with limited 
experimental information. The validity of the 
study cannot be evaluated.  
Chromosomal 
aberration 
Chinese hamster ovary 
cells 
0, 7.5 µg/ml  Negative(a)  (Aaron et al., 
1985) 
Only an abstract is available with limited 
experimental information. The validity of the 
study cannot be evaluated.  
Sister chromatic 
exchange 
Chinese hamster ovary 
cells 
0, 7.5 µg/ml  Positive(c)  
Negative(b) 
(Aaron et al., 
1985) 
Only an abstract is available with limited 
experimental information. The validity of the 
study cannot be evaluated. 
Cyclohexanol 
[02.070] 
Ames test  S. typhimurium TA98, 
TA1535, TA1537, 
TA1538 
500–10 000 
µg/plate3 
500–15 000 
µg/plate2 
Negative(a)  (Barsky, 
1976) 
The highest concentrations showed 
cytotoxicity. The study is considered valid. 
 Ames test  S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
0, 10–3333 
µg/plate 
Negative(a)  (Haworth et 
al., 1983) 
The highest level tested was the highest of 
either 10000 µg/plate, limit of solubility or 
maximal non-toxic concentration. Both rat 
and hamster liver S9 were used. The test was 
run twice. The study is considered valid. 
 Chromosomal 
aberration 
Human leukocytes  0.1–10 mM  Inconclusive(c) (Collin, 1971) The study report contains little experimental 
detail. Gaps, but no increase in breaks, were 
observed without any dose response 
relationship. There was no information with 
respect to cytotoxicity or presence of a 
control group. Only a statement on 
observations from 12 cells per concentration 
was given, but the total number of cells 
studied was not specified. The study is 
inadequate. 
(Cyclohexyl acetate 
[09.027]) 
DNA damage B. subtilis H17(rec+), 
M45 (rec–) 
19 mg/disc Negative(a) (Yoo, 1986)  
(Cyclohexyl 
butyrate [09.230]) 
DNA damage B. subtilis H17(rec+), 
M45 (rec-) 
19 mg/plate Negative(a) (Oda et al., 
1979) 
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Chemical Name 
[FL-no]  
Test System Test Object  Concentration Result  Reference  Comments  
(Cycopentanone 
[07.149]) 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
2.5–2500 
mg/plate 
Negative(a) (Florin et al., 
1980) 
 
(2,2,6-Trimethyl 
cyclo-hexanone 
[07.045]) 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
4.2–3600 
mg/plate 
Negative(a) (Florin et al., 
1980) 
 
Methyl 3-oxo-2-
pentyl-1-
cyclopentylacetate 
[09.520] 
Reverse mutation S. typhimurium TA98, 
TA100, TA102, 
TA1535,TA1537 
5 mg/plate Negative(a) (Thompson, 
2000) 
Valid study in compliance with the OECD 
Guideline 471. 
 Reverse mutation E. coli WP2 uvrA 5 mg/plate Negative(a) (Wagner and 
Klug, 2000) 
Valid study in compliance with the OECD 
Guideline 471. 
 Forward mutation Test Mouse lymphoma cells 
L5178y 
200 & 300µg/L 
300 µg/L 
Positive(c) 
Positive(c) 
(Ross and 
Harris, 1979) 
Pre-GLP study - not possible to assess the 
reliability of these studies. 
 Forward mutation Test Mouse lymphoma cells 
L5178y 
100–325 µg/L Negative(a) (Cifone, 2001) Valid study and in compliance with OECD 
Guideline 476. 
(Carveol [02.062]) Ames test (pre-
incubation) 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
560 µg/plate Negative (Mortelmans 
et al., 1986) 
 
(Carvyl acetate 
[09.215]) 
Ames test (pre-
incubation) 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
333 µg/plate Negative (Mortelmans 
et al., 1986) 
 
(L-menthyl (R,S)-3-
hydroxybutyrate) 
Reverse mutation S. typhimurium TA98, 
TA100, 
TA1535, TA1537 and 
TA1538 
78, 156, 312, 
625, 1250, 
2500 or 10 000 
µg/plate 
Negative(a), (f) (Morimoto, 
2005) 
The JECFA evaluated the racemate of L-
menthyl (R,S)-3-hydroxybutyrate. 
 Reverse mutation E. coli WP2uvrA 78, 156, 312, 
625, 1250, 
2500 or 10 000 
µg/plate 
Negative(a), (f) (Morimoto, 
2005) 
 
 NA: Not applicable. 
 NR: Not reported. 
(a): With and without S9 metabolic activation. 
(b): With S9 activation. 
(c): Without S9 activation. 
(d): Calculated based on molecular weight of menthol = 156.3 g/mol. 
(e): Marked differential toxicity was seen at dose levels above 25 µmol/plate. No observations were noted at lower dose levels. 
(f): Modified preincubation method. 
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Table 5:  Genotoxicity data (in vivo) evaluated by EFSA in FGE.09Rev3 (substances in brackets are JECFA-evaluated substances) 
Chemical Name 
[FL-no]  
Test System Test Object  Route Dose Reported 
Result  
Reference  Comments 
(Menthol [02.015]) Host mediated 
mutation assay 
S. typhimurium  
TA1530 and G46;  
S. cerevisiae D3 
inoculated in mice 
(7-9 
animals/group) 
Gavage  0, 1.45–5000 
mg/kg bw (single 
dose) 
0, 1150 mg/kg 
bw per day 
(repeated doses) 
Equivocal (Food and Drug 
Research 
Laboratories, Inc., 
1975) 
Negative results, with exception of the 
combination S. typhimurium  
TA1530 – 5000 mg/kg bw and S. 
cerevisiae D3 – 1150 mg/kg bw per day. 
This study is considered valid, but the 
equivocal result might have low 
relevance since the effect was only 
observed at very high (lethal) dose 
levels. 
 In vivo 
cytogenetic 
assay 
Male rat bone 
marrow cells 
Gavage 0, 1.45–3000 
mg/kg bw (single 
dose) 
0, 1150 mg/kg 
bw per day 
(repeated doses) 
Negative (Food and Drug 
Research 
Laboratories, Inc., 
1975)                            
Oral DL50 was determined as 940 mg/kg 
bw. The study is considered valid but the 
negative result is of limited relevance, 
since no effect on mitotic index was 
observed. However, testing at higher 
dose levels may not have been possible, 
due to lethality. 
 In vivo 
micronucleus 
assay 
B6C3F1 male 
mouse bone 
marrow cells 
Intra 
peritonal 
0, 250–1000 
mg/kg bw per 
day, during 3 
days 
Negative (Shelby et al., 
1993) 
d,l-Menthol was used. The study is 
considered valid, but the negative result 
is of limited relevance, since no toxicity 
to the bone marrow was observed. 
However, testing at higher dose levels 
was not possible, because the highest 
dose caused 50% lethality. 
 In vivo 
dominant lethal 
assay 
Male rat fertility, 
spermatozoa 
Gavage 0, 1.45–3000 
mg/kg bw (single 
dose) 
0, 1150 mg/kg 
bw per day 
(repeated doses) 
Negative (Food and Drug 
Research 
Laboratories, Inc., 
1975) 
This study is considered valid. 
(trans-Menthone 
[07.176]) 
In vivo SMART 
assay 
D. melanogaster 
– flr3 × mwh 
cross  
Whole 
body 
0, 1.3 µl/disk Positive (Franzios et al., 
1997) 
Somatic Mutation and Recombination 
Test. Only one dose level (1.29 µl/disk; 
slightlyhigher than the LD50) was tested.  
A two-fold increase in mutation 
frequency as compared to control was 
observed. Menthone was not 
recombinogenic. The validity of this study 
is unclear. 
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Chemical Name 
[FL-no]  
Test System Test Object  Route Dose Reported 
Result  
Reference  Comments 
(Cyclohexanone 
[07.148]) 
In vivo sex-
linked recessive 
lethal mutation 
D. melanogaster  NR 
3 days 
exposure 
0, 1 µl/mL Negative (Goncharova, 
1970) 
Article in Russian. Only an abstract 
available in English. The validity of this 
study cannot be assessed. 
Cyclohexanol 
[02.070] 
In vivo sex-
linked recessive 
lethal mutation 
D. melanogaster NR 
3 days 
exposure 
0, 1 µl/mL Negative (Goncharova, 
1970) 
The validity of the study cannot be 
evaluated. 
 In vivo 
micronucleus 
test 
NMRI mouse 
bone marrow  
Oral  500–1500  
mg/kg bw 
Negative (Gelbke, 1991) The study is considered valid. The 
negative result of this study is of limited 
relevance, since no bone marrow toxicity 
could be detected. Testing at higher dose 
levels might not have been possible due 
to observed general toxicity at the 
highest dose. 
Methyl 3-oxo-2-
pentyl-1-
cyclopentylacetate 
[09.520] 
Micronucleus 
test 
ICR mice Intra 
peritonal 
280, 560 & 1120 
mg/kg bw 
Negative (Gudi and 
Krsmanovic, 1998) 
Valid study in compliance with the OECD 
Guideline 474. 
 Unscheduled 
DNA Synthesis 
Rat hepatocytes Intra 
peritonal 
333.3 & 1000 
mg/kg bw 
Negative (Durward, 2001) Valid study in compliance with the OECD 
Guideline 486.  
NR: Not reported. 
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Table 6:  Genotoxicity data (in vitro) from FGE.211 
 [FL-no] 
[JECFA-
no]  
Chemical 
Name 
Test System  Test Object Concentrations of substance 
and test conditions 
Result  Reference  Comments 
09.930 
1098 
1(7),8-p- 
Menthadien-
2-yl acetate 
Reverse 
Mutation 
S. typhimurium TA98, TA100, 
TA1535, TA1537 and TA 102 
1.6*, 8*, 40*, 200, 1000 and 5000 
µg/plate (a), (b) 
Negative (Beevers, 2010)  
 S. typhimurium TA98, TA1535 
and TA1537 
15.6*, 31.3*, 62.5*, 125, 250 and 
500 µg/plate (b), (c) 
Negative   
 S. typhimurium TA100 and TA 
102 
78.1*, 156.3*, 312.5, 625, 1250 
and 2500 µg/plate (b), (c) 
Negative   
 S. typhimurium TA98 and 
TA100 
156.3*, 312.5, 625, 1250, 2500 
and 5000 µg/plate (d), (e) 
Negative   
 S. typhimurium TA1535, 
TA1537 and TA 102 
78.1*, 156.3*, 312.5, 625, 1250 
and 2500 µg/plate (d), (e) 
Negative   
 S. typhimurium TA100 25*, 50*, 100*, 200 and 400 
µg/plate (b), (c) 
Negative   
 S. typhimurium TA98 50*, 100*, 200*, 400 and 800 
µg/plate (d), (e) 
Negative   
 S. typhimurium TA100, 
TA1535, TA1537 and TA 102 
25*, 50*, 100*, 200 and 400 
µg/plate (d), (e) 
Negative   
 Micronucleus 
induction 
Human peripheral blood 
lymphocytes 
80, 90 and 110 µg/mL (c), (f); 
200, 300 and 400 µg/mL (e), (f) 
Negative (Whitwell, 2010) 50 to 65% 
cytotoxicity at top 
concentrations 
   20, 50, 80 and 100 µg/mL 
(c), (g) 
Negative   
* concentration without cytotoxicity 
(a): With and without S9 metabolic activation. 
(b): Plate incorporation method. 
(c): Without S9 metabolic activation. 
(d): Pre-incubation method. 
(e): With S9 metabolic activation. 
(f): 3-h incubation with 21-h recovery period. 
(g): 24-h incubation with no recovery period.  
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Table 7:  Genotoxicity data (in vitro) from FGE.212Rev1 
Chemical 
Name  
[FL-no]  
Test System Test Object  Concentration Reported 
Result  
Reference  Comments (e)  
Tetramethyl 
ethylcyclohexeno
ne (mixture of 
isomers [07.035] 
Reverse 
mutation 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537, TA1538 
 5 concentrations 
up to cytotoxicity, 
or max. 3600 
µg/plate 
Negative(a) (Wild et al., 
1983) 
Limited validity (no TA 102 or E. Coli); possibly 
slightly low maximal concentration tested. 
3,5,5-
Trimethylcyclohe
x-2-en-1-one 
[07.126] 
Reverse 
mutation 
S. typhimurium TA97, 
TA98, TA100, TA1535, 
TA1537 
33–10 000 
µg/plate 
Negative(a) (Mortelmans et 
al., 1986) 
Valid. 
 Mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
33–10 000 
µg/plate 
Negative(a) (NTP, 1986) NTP study carried out according to standard US-
EPA guideline; result is considered as valid. 
 Mutation L5178YTk+/– mouse 
lymphoma cells 
67–810 µg/mL Negative(b) (McKee et al., 
1987) 
Validity cannot be evaluated (tested with S9; 
abstract only with very limited information). 
 Mutation L5178YTk+/– mouse 
lymphoma cells 
130–1300 µg/mL Negative(c) (McKee et al., 
1987) 
Validity cannot be evaluated (tested without S9; 
abstract only with very limited information). 
 Mutation L5178YTk+/– mouse 
lymphoma cells 
0.089–0.89 µl/mL Negative(c) (O’Donoghue et 
al., 1988) 
Valid according to current guidelines. 
 Mutation L5178YTk+/– mouse 
lymphoma cells 
0.13–1.3 µl/mL Negative(b)  (O’Donoghue et 
al., 1988) 
Valid according to current guidelines. 
 Mutation L5178YTk+/– mouse 
lymphoma cells 
1200 µg/mL Positive(b) (NTP, 1986) NTP study carried out according to standard US-
EPA guideline; Not tested with S9. Result is 
considered as valid. 
 Mutation L5178YTk+/– mouse 
lymphoma cells 
Not reported 
(however, up to 
cytotoxic 
concentrations) 
for 3 h exposure.  
Negative(a) (Honma et al., 
1999a) 
Limited validity since data was presented in a 
summarised table format only (as a result of an 
international collaborative study). 
 Mutation L5178YTk+/– mouse 
lymphoma cells 
Up to 1500 
µg/mL 
Positive(b) 
 
(Honma et al., 
1999b) 
Limited validity since mutation frequencies were 
not reported in table format. Tested only in the 
absence of S9. Isophorone was mutagenic after  
24 h treatments in the absence of S9. Although 
only graphs are plotted, it seems that increases in 
MF that exceeded the Global Evaluation Factor 
occurred at around 1250-1500 µg/mL where 
toxicity (by relative survival) reached 70-90%. 
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Chemical 
Name  
[FL-no]  
Test System Test Object  Concentration Reported 
Result  
Reference  Comments (e)  
 Chromosomal 
aberration 
Chinese hamster ovary 
cells 
5–1600 µg/mL Negative(a) (Gulati et al., 
1989) 
Limited validity (not clear if gaps were included in 
the scores). 
 Chromosomal 
aberration 
Chinese hamster ovary 
cells 
250–1600 µg/mL Negative(a) (NTP, 1986) NTP study carried out according to standard US-
EPA guideline; result is considered as valid. 
 Chromosomal 
aberration  
Chinese hamster lung 
fibroblasts  
0–1250b µg/mL  
0–1500c µg/mL 
Positive(a) (Matsuoka et al., 
1996) 
Valid. 
 Chromosomal 
aberration  
Chinese hamster lung 
fibroblasts  
250–1000 mg/mL Negative(a) (Matsuoka et al., 
1996) 
Valid. Exposed to isophorone without metabolic 
activation for 24 h or 48 h, cytotoxic at highest 
concentrations. 
 Sister 
chromatid 
exchange 
Chinese hamster ovary 
cells 
5–1600 mg/mL Positive(b), (d)  (Gulati et al., 
1989) 
Valid (pos – S9; neg + S9). 
 Sister 
chromatid 
exchange 
Chinese hamster ovary 
cells 
160–1000 mg/mL Negative(a) (NTP, 1986) Valid. NTP study carried out according to Standard 
US-EPA guideline; result is considered as valid. 
 Unscheduled 
DNA synthesis 
Rat hepatocytes 0.005–0.4 µl/mL Negative (O’Donoghue et 
al., 1988) 
Valid according to current guidelines 
 Unscheduled 
DNA synthesis 
Rat hepatocytes 5–200 µl/mL Negative(a) (McKee et al., 
1987) 
Validity cannot be evaluated (abstract only with 
very limited information). 
Carvone (isomer 
not specified) 
Gene mutation S. typhimurium TA1535, 
TA1537, TA98, TA100 
3 µmol/plate Negative (Florin et al., 
1980) 
Insufficient validity (spot test, not according to 
OECD guideline, methods and results insufficiently 
reported). Isomer (D or L) not reported. 
 Rec assay  Bacillus subtilis H17 
(rec+) and M45 (rec-) 
0.6 mL/disc Negative (Matsui et al., 
1989) 
The test system used is considered inappropriate.  
d-Carvone 
[07.146] 
Gene mutation S. typhimurium TA1535, 
TA98, TA100, 
TA1537 
333 µg/plate Negative(a) (NTP, 1990) Valid 
 Gene mutation 
(preincubation) 
S. typhimurium TA1535, 
TA98, TA100, 
TA1537 
560 µg/plate Negative (Mortelmans et 
al., 1986) 
Valid 
 Sister 
chromatid 
exchange 
Chinese hamster ovary 
cells 
502 µg/mL Positive(a) (NTP, 1990) Valid 
 Chromosomal 
aberration 
Chinese hamster ovary 
cells 
400 µg/mL Positive(a) (NTP, 1990) Valid 
(a): With and without S9 metabolic activation. 
(b): Without S9 metabolic activation. 
(c): With S9 metabolic activation. 
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(d): Cytotoxic at next highest dose tested (1600 mg/mL) 
(e): Validity of genotoxicity studies: 
Valid. 
Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation).  
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system). 
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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Table 8:  Genotoxicity data (in vivo) from FGE.212Rev1 
Chemical Name  
[FL-no]  
Test System Test Object  Route Dose Result  Reference  Comments(a)  
Tetramethyl 
ethylcyclohexenone 
(mixture of isomers 
[07.035] 
Sex-linked 
recessive 
lethal 
mutation 
D. melanogaster Feed  10 mM Negative (Wild et al., 
1983) 
Limited validity (low nr of chromosomes, 
limited reporting). 
 Micronucleus 
formation 
Mouse bone marrow i.p. 180, 307, 450 
mg/kg bw 
Negative (Wild et al., 
1983) 
Limited validity. Only analysis at one time 
point; no PCE/NCE ratio reported. 
3,5,5-
Trimethylcyclohex-2-
en-1-one [07.126] 
Sex-linked 
recessive 
lethal 
mutation 
D. melanogaster  2000(b)  and  
12 500(c)  mg/kg 
Negative (Foureman et 
al., 1994) 
Valid, however, only limited relevance. 
 Micronucleus 
formation 
CD-1 mice i.p. 540 mg/kg bw 
(MTD) 
Negative (McKee et al., 
1987) 
Validity cannot be evaluated. Abstract only; 
very limited information no data on PCE/NCE 
ratio. 
 Micronucleus 
formation 
CD-1 mice i.p. 0.54 mL/kg bw Negative (O’Donoghue et 
al., 1988) 
Limited validity. Only one dose level tested, 
this dose level corresponded to the LD20; 
sample schedule inadequate. 
 Chromosomal 
aberration 
B6C3F1 mice i.p. 125, 250, 500 
mg/kg bw 
Negative (NTP Website, 
1990) 
Valid. Submitted by Industry in 2009. The 
standard protocol for in vivo CA is not given 
on the NTP website. However, based on 
Shelby and Witt (1995), animals should have 
been sampled at 17 h and, if negative, also 
at 36 h. The data on the NTP website are 
only for bone marrow sampled at 36 h. It is 
therefore possible that a 17 h sample was 
also taken, and found to be negative, but the 
data not posted. Fifty cells per animal were 
scored for CA and no increases in CA were 
seen. No measures of toxicity were recorded, 
but i.p. dosing should have guaranteed 
systemic exposure. 
 DNA binding F344 rats Gavage 500 mg 
unlabelled 
isophorone/kg bw 
spiked with 14C-
isophorone (0.4 
mCi/rat) 
Negative (Thier et al., 
1990) 
Limited validity. Submitted by Industry in 
2009. No positive controls and no untreated 
controls used. Liver and kidney were 
analysed. 
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 DNA binding B6C3F1 mice Gavage 500 mg 
unlabelled 
isophorone/kg bw 
spiked with 14C-
isophorone (0.08 
mCi/mouse) 
Negative (Thier et al., 
1990) 
Limited validity. Submitted by Industry in 
2009. No positive controls and no untreated 
controls used. Liver and kidney were 
analysed. 
 DNA binding F344 rats (10 males) Gavage 500 mg/kg bw 
14C-isophorone 
(0.1 mCi/rat) 
Negative (Morishita et al., 
1997) 
Valid. Preputial glands and kidneys were 
analysed. 
 DNA adducts 
(32P-
Postlabelling) 
F344 rats (7 males 
and 7 females per 
dose group) 
Gavage 0 and 500 mg/kg 
per day for 5 
days. 
Negative (Morishita et al., 
1997) 
Valid. Preputial glands were analysed. 
(a): Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
(b): Oral administration. 
(c): Injection. 
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Table 9:  Genotoxicity data (in vitro) from FGE.212Rev3 
Chemical Name  
[FL-no]  
Test 
System 
Test Object  Concentration Reported 
Result  
Reference  Comments  
3-Methyl-2-
cyclopenten-2-one 
[07.112] 
Reverse 
mutation 
S. typhimurium TA98, TA100, 
TA1535, TA1537, TA102 
5–5000 µg/mL Negative(a) (Bowen, 2014) TA98 showed toxicity at 160 µg/mL. 
 Micronucleus 
Assay 
Human peripheral blood 
lymphocytes 
600, 800 and 962 µg/mL Negative (Watters, 2014)  
(a): With and without S9 metabolic activation. 
 
Table 10:  Additional genotoxicity data (in vitro)  
 
[FL-no]  
EU Register 
name 
JECFA name 
Structural  
formula  
End-point Test system  Maximum 
concentration 
Results Reference 
07.148 
1100 
Cyclohexanone 
 
Reverse mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
33–3333 
µg/plate 
Negative(a) (NTP, 2007) 
  Mutation Mouse lymphoma 
L5178Y Tk+/- cells 
312.5–5000 
µg/mL 
Negative (NTP, 2007) 
(a): With and without S9 metabolic activation. 
  
O
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Appendix B – Summary of Safety Evaluations 
Table 11:  Summary of safety evaluation of alicyclic ketones, secondary alcohols and related esters (JECFA, 2003) 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI 
(a)  
US MSDI 
(µg/capita 
per day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome 
on the 
named 
compound 
(d) or (e) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
02.209 
1099 
3,3,5-
Trimethylcyclohe
xan-1-ol 
OH
 
0.12 
0.1 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.027 
1093 
Cyclohexyl 
acetate 
O
O
 
12 
10 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.140 
1097 
Cyclohexyl 
propionate 
O
O
 
0.012 
0.05 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.160 
1095 
Cyclohexyl 
formate 
O
O
 
0.012 
0.2 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI 
(a)  
US MSDI 
(µg/capita 
per day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome 
on the 
named 
compound 
(d) or (e) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
09.230 
1094 
Cyclohexyl 
butyrate 
O
O
 
0.89 
0.1 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
09.464 
1096 
Cyclohexyl 
isovalerate 
O
O
 
0.28 
0.05 
Class I 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.033 
1115 
Isojasmone O
+
O
 
0.37 
0.01 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev3, 
genotoxicity concern could be 
ruled out. No safety concern at 
the estimated level of intake 
based on the MSDI approach. 
CAS Nr in Register to be 
checked. CASrn in Register 
refers to 2-cyclopenten-1-
one, 2-methyl-3-(2-penten-
1-yl). Additional 
information indicates 
that this substance 
consists of 2-hexyl-2-
cyclopent-1-one + 2-
pentyl-2-cyclohexen-1-
one. However the CAS 
nrs provided do not 
correspond with these 
structures. Therefore, 
this substance will not 
be further evaluated in 
the current revision of 
this FGE. 
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FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI 
(a)  
US MSDI 
(µg/capita 
per day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome 
on the 
named 
compound 
(d) or (e) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
07.034 
1106 
2-
Hexylidenecyclo
pentan-1-one 
O
 
0.24 
0.01 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.211, 
genotoxicity concern could be 
ruled out.  No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.035 
1111 
Tetramethyl 
ethylcyclohexen
one (mixture of 
isomers) 
OO
29 % 68 %
+
7.8 
0.2 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out.  No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.045 
1108 
2,2,6-
Trimethylcyclohe
xanone 
O
 
2.1 
0.04 
Class II 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.094 
1114 
3-Methyl-2-
(pent-2(cis)-
enyl)cyclopent-
2-en-1-one 
O
 
13 
7.2 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev3, 
genotoxicity concern could be 
ruled out. No safety concern at 
the estimated level of intake 
based on the MSDI approach. 
According to JECFA: Min. 
assay value is ‘98 cis’. No 
safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.095 
1109 
2-(sec-
Butyl)cyclohexan
one 
O
 
5.1 
ND 
Class II 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
According to JECFA: Min. 
assay value is ‘94%’ and 
secondary components ‘2-
Isobutyl cyclohexanone’ 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.098 
1107 
3-
Methylcyclohex-
2-en-1-one 
O
 
0.012 
0.1 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out.  No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
        
Flavouring Group Evaluation 51, Revision 2 
 
 
www.efsa.europa.eu/efsajournal 51 EFSA Journal 2016;14(1):4338 
 
 
FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI 
(a)  
US MSDI 
(µg/capita 
per day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome 
on the 
named 
compound 
(d) or (e) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
07.112 
1105 
3-Methyl-2-
cyclopenten-1-
one 
O
 
0.06 
ND 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev3, 
genotoxicity concern could be 
ruled out. No safety concern at 
the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.126 
1112 
3,5,5-
Trimethylcyclohe
x-2-en-1-one 
O
 
4.6 
0.1 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out.  No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.129 
1113 
3-Methyl-5-
propylcyclohex-
2-en-1-one 
O
 
0.097 
4.1 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out.  No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.140 
1406 
3-Methyl-2-
pentylcyclopent-
2-en-1-one 
O
 
0.34 
0.2 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev3, 
genotoxicity concern could be 
ruled out. No safety concern at 
the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.148 
1100 
Cyclohexanone O
 
0.12 
0.1 
Class II 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.149 
1101 
Cyclopentanone O
 
0.018 
0.02 
Class II 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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FL-no 
JECFA-
no 
EU Register 
name 
Structural formula EU MSDI 
(a)  
US MSDI 
(µg/capita 
per day) 
Class (b) 
Evaluation 
procedure 
path (c) 
Outcome 
on the 
named 
compound 
(d) or (e) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
07.172 
1110 
4-
Isopropylcyclohe
x-2-en-1-one 
O
 
0.0012 
0.001 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.212Rev1, 
genotoxic concern could be 
ruled out.  No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.179 
1102 
2-
Methylcyclohexa
none 
O
 
0.12 
0.1 
Class II 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
Racemate. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
07.257 
1117 
2-(3,7-Dimethyl-
2,6-octadienyl) 
cyclopentanone 
O
 
3 
6.6 
Class II 
A3: Intake 
below 
threshold 
d No safety concern at the 
estimated level of intake based 
on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
 
09.930 
1098 
Cyclohexyl, 2-
methylene-5-(1-
methylethenyl) 
acetate 
O O
 
0.61 
0.6 
Class II 
A3: Intake 
below 
threshold 
d Evaluated in FGE.211, 
genotoxicity concern could be 
ruled out.  No safety concern 
at the estimated level of intake 
based on the MSDI approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
ND: not determined 
(a): EU MSDI: Amount added to food as flavour in (kg / year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365)  = µg/capita per day. 
(b): Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Table 12:  Summary of safety evaluation of supporting substances as evaluated in FGE.09rev6 (EFSA CEF Panel, 2015b), applying the Procedure 
FL-no 
JECFA-
no 
EU Register name Structural formula MSDI (a) 
(µg/capita  
per day) 
 
Class (b) 
Evaluation 
procedure path 
(c) 
Outcome on 
the named 
compound 
(d) or (e) 
Outcome on the 
material of 
commerce (f), (g), (h) 
Evaluation 
remarks 
02.070 
 
Cyclohexanol OH
 
3.7 
 
Class I 
A3: Intake below 
threshold 
d f  
02.075 
 
(1R,2S,5S)-neo-
Dihydrocarveol OH
 
2.4 
 
Class I 
A3: Intake below 
threshold 
d f  
02.135 
 
Cyclopentanol OH
 
0.012 
 
Class I 
A3: Intake below 
threshold 
d f  
02.167 
 
(1R,2R,5S)-
Isodihydrocarveol OH
 
2.4 
 
Class I 
A3: Intake below 
threshold 
d f  
09.154 
1852 
Menthyl valerate 
O
O
 
1 
 
Class I 
A3: Intake below 
threshold 
d f  
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FL-no 
JECFA-
no 
EU Register name Structural formula MSDI (a) 
(µg/capita  
per day) 
 
Class (b) 
Evaluation 
procedure path 
(c) 
Outcome on 
the named 
compound 
(d) or (e) 
Outcome on the 
material of 
commerce (f), (g), (h) 
Evaluation 
remarks 
09.355 
 
neo-Dihydrocarvyl 
acetate O
O
 
0.012 
 
Class I 
A3: Intake below 
threshold 
d f  
09.618 
 
Menthyl formate 
OO
 
0.73 
 
Class I 
A3: Intake below 
threshold 
d f  
09.619 
 
(1R,2S,5R)-Menthyl 
hexanoate O
O
 
0.37 
 
Class I 
A3: Intake below 
threshold 
d f  
09.621 
 
(1R,2S,5R)-Menthyl 
salicylate 
OHO
O
 
0.012 
 
Class I 
A3: Intake below 
threshold 
d f  
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FL-no 
JECFA-
no 
EU Register name Structural formula MSDI (a) 
(µg/capita  
per day) 
 
Class (b) 
Evaluation 
procedure path 
(c) 
Outcome on 
the named 
compound 
(d) or (e) 
Outcome on the 
material of 
commerce (f), (g), (h) 
Evaluation 
remarks 
09.843 
 
Menthol 1-and 2-
propylene glycol 
carbonate 
OH
O
O
O
+
O O
OH
O
830 
380 
Class I 
A3: Intake below 
threshold 
d g  
09.870 
 
Carvyl-3-methylbutyrate 
O
O
 
0.0012 
 
Class I 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.212, 
genotoxicity 
concern could 
be ruled out. 
09.929 
 
L-Monomenthyl glutarate 
O
O
O
OH
 
110 
 
Class I 
A3: Intake below 
threshold 
d f  
09.935 
 
Dimenthyl glutarate 
O
O
O
O
 
30 
 
Class I 
A3: Intake below 
threshold 
d f  
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FL-no 
JECFA-
no 
EU Register name Structural formula MSDI (a) 
(µg/capita  
per day) 
 
Class (b) 
Evaluation 
procedure path 
(c) 
Outcome on 
the named 
compound 
(d) or (e) 
Outcome on the 
material of 
commerce (f), (g), (h) 
Evaluation 
remarks 
09.949 
 
L-Menthyl (S)-3-
hydroxybutyrate 
O
O OH
 
37 
 
Class I 
A3: Intake below 
threshold 
d f  
07.059 
 
p-Menthan-3-one 
O
 
530 
2,500 
Class II 
A3: Intake below 
threshold 
d f  
07.109 
1857 
2,6,6-Trimethylcyclohex-
2-en-1,4-dione 
O
O
 
50 
 
Class II 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.213Rev1, 
genotoxicity 
concern could 
be ruled out. 
07.202 
 
2,6,6-Trimethylcyclohex-
2-en-1-one 
O
 
0.12 
 
Class II 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.212Rev1, 
genotoxicity 
concern could 
be ruled out. 
07.203 
 
3,3,5-
Trimethylcyclohexan-1-
one 
O
 
0.0085 
 
Class II 
A3: Intake below 
threshold 
d f  
07.219 
 
trans-3-Methyl-2-(2-
pentenyl)-2-cyclopenten-
1-one 
O  
4.7 
 
Class II 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.212Rev3, 
genotoxicity 
concern could 
be ruled out. 
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FL-no 
JECFA-
no 
EU Register name Structural formula MSDI (a) 
(µg/capita  
per day) 
 
Class (b) 
Evaluation 
procedure path 
(c) 
Outcome on 
the named 
compound 
(d) or (e) 
Outcome on the 
material of 
commerce (f), (g), (h) 
Evaluation 
remarks 
07.255 
1856 
l-Piperitone 
O
R
 
12 
 
Class II 
A3: Intake below 
threshold 
d f Evaluated in 
FGE.212Rev1, 
genotoxicity 
concern could 
be ruled out. 
07.207 
 
Cyclotetradecanone 
CH2
CH2
CH2
CH2
CH2
CH2C
H2
H2C
H2C
H2C
H2C
H2C
H2C
O
 
0.061 
 
Class II 
B3: Intake below 
threshold, B4: No 
adequate NOAEL 
Additional data 
required 
 No longer 
supported by 
Industry (EFFA, 
2009). 
09.520 
1898 
Methyl 3-oxo-2-pentyl-1-
cyclopentylacetate 
O
O
O
 
770 
 
Class II 
A3: Intake above 
threshold, A4: Not 
endogenous, A5: 
Adequate NOAEL 
exists 
d f  
06.136 
1859 
6-Isopropyl-3,9-dimethyl-
1,4-dioxyspiro[4.5]decan-
2-one 
O
O
O  
1.2 
 
Class III 
A3: Intake below 
threshold 
d f  
(a): EU MSDI: Amount added to food as flavour in (kg / year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365) = µg/capita per day. 
(b): Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h): No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
